



Summary

In their constant strive for innovation, outsourcing has become essential for biopharmaceutical companies. Contract research organizations (CROs) are independent service providers that help biopharmaceutical companies manage their drug development process. With their expertise in preclinical and clinical R&D, CROs have become key enablers and strategic partners for the biopharmaceutical industry.

Germany provides access to a vibrant and highly diversified contract research landscape. CROs deliver high-quality services along the drug development pathway and meet the exacting demands of drug developers – from end-to-end development to tailored contract research activities.

HEALTH MADE IN GERMANY has compiled this directory to give you an overview of companies active in Germany's CRO sector. The purpose of this directory is twofold: First, to provide an introduction to the country's contract research landscape. And secondly, to help you to quickly find services of interest to your business. As such, the directory is an invaluable resource that also provides the tools necessary for you to take the next step – establishing contact with the appropriate partners in your area of activity.

Content

INTRODUCTION

- Managing the drug development process
- 5 CROs as key players in pharma innovation
- 6 Growing and maturing CRO landscape
- 7 Different models of cooperation
- 7 Spectrum of services offered by CROs
- 7 Strengths of CROs in Germany
- 8 Drug discovery and preclinical studies
- 9 Clinical CRO landscape
- 10 **COMPANY PROFILES**
- 11 Company and technology overview
- 16 Company profiles
- 72 **OUR PARTNERS Industry Associations**
- 74 **OUR SERVICES**
- 75 **CONTACT**
- 75 **IMPRINT**



Contract research organizations (CROs) are independent service providers in the drug development process. They provide a range of services to pharmaceutical, biotechnology, and medical device companies as well as governments, academic institutions, and other research entities. These services can encompass all phases of the drug development life cycle – from compound selection, discovery, pre-clinical and clinical research to post-approval services including commercialization, safety assessment, monitoring, and consulting.

Managing the drug development process

Contract research organizations help biopharmaceutical companies manage the drug development process. Thanks to their expertise, they are often able to do so more cost effectively and with a shorter time-to-market than inhouse R&D departments. CROs fall into several categories. Preclinical CROs test drug or device candidates for client businesses before the compounds or devices undergo clinical or human testing. This might include helping a client to synthesize compounds, run biochemical assays or conduct animal studies. Clinical CROs focus on clinical trial services such as medical writing, regulatory submissions, project management, monitoring, data management and analysis,

laboratory services, other functions associated with getting new drugs or devices to market.

There are more than a dozen global full-service CROs that offer the complete spectrum of services needed for drug development. These larger CROs generally provide services to large pharma companies. A growing number of smaller speciality CROs provide tailored services that focus on a particular stage of clinical development or offer defined services within a specific therapeutic niche - largely addressing smaller and mid-sized pharma clients. This flexibility and know-how is also becoming increasingly attractive for Big Pharma clients. Germany provides access to a broad range of CROs in a vibrant and highly diversified contract research landscape that covers all stages in drug development and value creation.




Outsourcing has become a standard procedure in the age of agile and flexible pharma development.

CROs as key players in pharma innovation

The innovation landscape of the global pharma industry has changed dramatically over the past decade. The whole industry – and Big Pharma in particular – has experienced stricter regulatory requirements, escalating commercialization costs and patent expirations on key blockbuster drugs. In order to increase drug-discovery program success rates and reduce R&D costs, pharmaceutical companies seek to improve and accelerate

The industry's pipeline includes a diverse mix of new technologies






for the biopharmaceutical industry. The current situation has evolved against the backdrop of an innovation landscape driven by exponentially growing biomedical information, powerful emerging technologies, and the increasing importance of interdisciplinary collaboration. These developments allow drug makers to cover a broader range of medical needs than in the past. The pharma pipeline has also diversified and is moving from one dominated by small molecules and monoclonal antibodies to a wide spectrum of new technologies and modalities. Examples of this include immuno-oncology moving from a niche interest to the mainstream, the dawn of cellular therapies, and the resurgence of gene therapies. Enhanced drug complexity brings with it an even higher complexity of associated clinical trials, requiring special planning, conducting and analyzing expertise.

every stage of the drug development process. Pharmaceutical companies are increasingly turning to agility and flexibility concepts in order to reduce costs and speed up time-to-market for novel therapeutic and diagnostic products. They are downsizing their in-house capacities and increasingly outsourcing their research activities to independent service providers. With the advent of a maturing CRO industry, outsourcing has become a standard procedure in pharma R&D. As a result, CROs have become key players

Growing and maturing CRO landscape

The CRO industry has been growing steadily. It has benefited from recent downsizing trends in combination with growing R&D pipelines in Big Pharma, as well as from a proliferation of smaller drug makers (Tufts CSDD 2019). Outsourcing their R&D to CROs allows smaller or sometimes fully virtualized companies to manage drug development programs with minimal infrastructure. CRO market forecasts vary among different analysts. In 2018, the global CRO services market was estimated to be worth USD 37

Global CRO market and penetration rates (In-house vs. Outsourced) in percent



Original: resultshealthcare.com (Source: Baird, 2015; CRO Industry Primer, Credit Suisse, 2016; 2017 CRO Market Size Projections 2016–2021, ISR Reports, 2017)

billion (Results Healthcare "CRO sector" 2019). The outsourcing penetration level is expected to increase to 60 percent in 2020. Market researchers predict that more than one third of all global drug-discovery research will be outsourced to CROs by 2021 (Kalorama Information "Outsourcing in Drug Discovery" report 2018).

Different models of cooperation

The way biopharma companies work with CROs has changed tremendously. Once driven by "tactical" or "functional outsourcing" considerations, the CRO industry now takes on a much larger and more complex role in pharma R&D. For the pharma client, CROs have become strategic development and cooperation partners that base their business model on enabling technologies that guarantee higher quality and more efficient R&D process execution. Nowadays, there are various models of collaboration between sponsors and CROs. These include the outsourcing of functional teams ("resourcing"), asset transfer, and risk sharing. It is clear that not only the number of CROs has increased, but that they have grown by accumulating knowledge and expertise beneficial to their clients.

Spectrum of services offered by CROs


R&D tasks that biopharma companies choose to outsource include a wide spectrum of activities from basic research to late-stage development. The clinical and post-approval stages are the most complex and regulatory intense stages of development. Therefore these are the stages where clients require the most input from specialist outsourced providers. This is reflected by the size of the respective market (see figure CRO market size by activity).

Strengths of CROs in Germany

As part of this dynamic global landscape, there are several hundred preclinical and clinical CROs based in Germany that can deliver high-quality services along the drug development pathway – from end-to-end development to tailored contract research activities. Germany is the top pharma market in Europe and number four worldwide. It is also a heavyweight in medical biotechnology. The range of advanced high technologies on offer, an excellent biomedical research and clinical infrastructure makes the German market truly unique. Germany offers a vital and highly diversified contract research landscape, with CROs covering all stages of drug development and value creation. The county is

CRO market size by activity

in billion USD



Source: Credit Suisse (Company data, EvaluatePharma, Credit Suisse estimates)

home to a strong network of specialized CROs covering a broad range of services supporting drug developers to remain innovative and competitive, flexible and agile. The versatility and strength of the German CRO landscape is a solid reference point for collaboration at the international level.

The majority of the 112 German contract research providers presented in this guide fall into the category of small and medium-sized enterprises (SMEs). This directory of companies mirrors the multifaceted nature of the research services offered by CROs in Germany along the value chain. Not all companies exclusively offer research services – many carry out their own drug research and development but also offer contract research services as a side activity.





Drug discovery and preclinical studies

Some companies focus on the synthesis of biomolecules such as DNA, RNA and peptides or the synthesis of small chemical molecules – all vital stages in pharmaceutical development. Others specialize in the analysis of those molecules that involve the characterization of structure, function, and expression. A number of high-profile laboratories in Germany apply bioanalytical techniques. This requires high-tech instrumental set-up and experienced know-how for data analysis – a field that Big Pharma is increasingly outsourcing to external specialists. Screening for potential drug candidate

molecules is another priority area for contract research service providers. Drug target discovery and molecular modelling of substances require the use of powerful bioinformatic and cheminformatic tools by necessity. Other companies are occupied with determining the pharmacologic characteristics of active substances towards an improved understanding of the efficacy and toxicology of drug candidates. Another extremely important area is preclinical studies: highly specialized cell culture and animal models are being deployed to elucidate new drug candidate uptake, metabolization, excretion, and toxicity. A major innovation in the drug discov-

From discovery to the market

CRO services along the value chain

	Drug discovery	Preclinical studies	Clinical trials: phase I–III	Post-approval
CRO services offered	Target identification & validation	Pharmacokinetics & toxicity testing	Planning, conducting,	Post-approval studies
	Hit identification	In vitro studies (cell culture)	 analyzing or reporting clinical trials 	Marketing authorization
	Lead optimization	In vivo studies (animal models)	Quality Assurance	-
		,	Laboratory or central services (e.g. imaging, ECG reading)	
			Traning/Consulting	-
			eSolutions	-

Source: BIOCOM

ery field is the advent of stem cell technologies such as cellular reprogramming. This method allows adult human cells to be converted into induced pluripotent stem cells (iPS cells). iPS cells are a resource to generate any cell type of the human body. They enable the generation of cell-based disease models. Biotech companies in Germany have expanded their drug screening activities in the stem cell field on a large scale.

Clinical CRO landscape

Internationally, Germany is renowned for its excellent academic and clinical research. It is also one of Europe's leading countries in terms of the number of clinical studies conducted. Clinical CROs organize and manage clinical studies from phase I to phase III and secure clinical trial monitoring, thereby delivering the muchneeded information basis required for approval. A number of central laboratories offer the full range of laboratory services in clinical research. Conducting phase I clinical studies is a particular strength of clinical CROs in Germany. With an

increasingly rich pool of biomedical and patient data - including genomic, proteomic, microbiome and biomarker data - to tap into, CROs active in clinical development have invested heavily in data technology and powerful IT system infrastructure. Collection and analysis of high-quality data is considered as being key to effective drug development processes. One area in which such data outputs are extremely valuable is real world data and real world evidence studies. When combined with big data, artificial intelligence and machine learning algorithms have the potential to greatly improve the clinical trial process. Another very successful niche German CROs occupy are eSolutions including the use of social media in patient recruitment or data management and statistical tools.

This guide illustrates the diversity, strength and depth of the German contract research landscape. We hope that it will be of assistance in helping you identify the services and expertise needed for your own successful drug development.



Germany is renowned for its clincial research – clinical CROs offer specialized services for this phase of drug development.





Company	Synthesis	Analysis & Characterisation	Bio-/ Chemoinformatics	Screening	Medical Chemistry	Galenics & Delivery	Pharmacodynamics, -kinetics	Cell Culture Technology	Bioanalytics	Diagnostic Services	Clinical Research
8sens.biognostic GmbH									•	•	
ABX-CRO advanced pharmaceutical services											
Accelero® Bioanalytics GmbH											
acromion GmbH											
Alcedis GmbH											
Allied Clinical Management GmbH											
AMP-Lab GmbH											
AMS Advanced Medical Services											
analyze & realize GmbH											
Antiinfectives Intelligence GmbH											
ARTES Biotechnology GmbH											
ASCA GmbH Angewandte Synthesechemie Adlershof	•										
Assay.Works GmbH											
ATLAS Biolabs GmbH			•								
Axolabs GmbH			•								
AZ Biopharm GmbH Berlin							•				•
Biaffin GmbH & Co KG											
Bicoll GmbH											
Bioassay GmbH											
biometec GmbH											
Biosyntan											
BIOTREND CHEMIKALIEN GmbH											
Carpegen GmbH											
CeGaT GmbH											
Celares GmbH	•										
cellasys GmbH											
CellServe GmbH											
CellTrend GmbH											
	_									_	

Company	Synthesis	Analysis & Characterisation	Bio-/ Chemoinformatics	Screening	Medical Chemistry	Galenics & Delivery	Pharmacodynamics, -kinetics	Cell Culture Technology	Bioanalytics	Diagnostic Services	Clinical Research
ChemCon GmbH											
Chimera Biotec GmbH							•				
CIRES cell & immune research services											
CONET GmbH											
Conreso GmbH											
Coriolis Pharma Research GmbH											
CROLLL GmbH											
CRS Clinical Research Services Andernach GmbH											
CTC North GmbH & Co. KG											
Cube Biotech GmbH											
Dr. Notghi Contract Research GmbH											
Dr. Regenold GmbH											
emovis GmbH											
ENDOTHERM GmbH	•										
Evotec SE											
eXcorLab GmbH											
Experimentelle Pharmakologie & Onkologie Berlin-Buch GmbH											
FGK Clinical Research GmbH											
Formula GmbH											
GALAB Technologies GmbH											
GBA Group Pharma											
GKM Gesellschaft für Therapieforschung mbH											
glyXera GmbH											
Health Research Services GmbH											
Heidelberg Pharma AG											
ICCR-Roßdorf GmbH											
Immundiagnostik AG											
INFAI			·								

Company	Synthesis	Analysis & Characterisation	Bio-/ Chemoinformatics	Screening	Medical Chemistry	Galenics & Delivery	Pharmacodynamics, -kinetics	Cell Culture Technology	Bioanalytics	Diagnostic Services	Clinical Research
Insilico Biotechnology AG											
Institut für Atemwegsforschung (INSAF) GmbH											
IQVIA RDS GmbH											
JPT Peptide Technologies GmbH											
KOEHLER eClinical GmbH											•
LEUKOCARE AG											
Life & Brain GmbH											
Lionex GmbH											
Lipotype GmbH											
Mediagnost GmbH											
Mediconomics GmbH											
MEDICRO GmbH											
menal GmbH											
Merck Chemicals GmbH	•										
metabion GmbH											
Metronomia Clinical Research GmbH											
micro-biolytics GmbH											
Microcoat Biotechnologie GmbH											
MicroDiscovery GmbH											
MicroMol GmbH											
Micromun											
Minerva Analytix GmbH											
MLM Medical Labs GmbH											
OakLabs GmbH											•
OmicScouts GmbH											
OmniComm Europe GmbH											
PEPperPRINT GmbH	•										
peptides&elephants GmbH											

Company	Synthesis	Analysis & Characterisation	Bio-/ Chemoinformatics	Screening	Medical Chemistry	Galenics & Delivery	Pharmacodynamics, -kinetics	Cell Culture Technology	Bioanalytics	Diagnostic Services	Clinical Research
PharmaInformatic											
PHARMALOG Institut für klinische Forschung GmbH											
PortaCellTec biosciences GmbH											
preclinics Gesellschaft für präklinische Forschung mbH											
Premier Research											
PRIMACYT Cell Culture Technology GmbH											
proDERM											
Profil Germany GmbH											
ProJect Pharmaceutics GmbH											
Prolytic GmbH											
Proteome Factory AG											
PXBioVisioN GmbH											
SanaClis DE GmbH											
SequentiX - Digital DNA Processing			•								
Seramun Diagnostica GmbH											
Sirius Fine Chemicals SiChem GmbH											
SSS International Clinical Research GmbH											
StarSEQ GmbH											
SynapCon Ltd.											
SYNLAB Analytics & Services Germany GmbH							•				
Taros Chemicals GmbH & Co. KG			•								
TherapySelect Dr. Frank Kischkel											•
TRIGA-S Scientific Solutions											
vertis Biotechnologie AG											
Vibalogics GmbH											
VivaCell Biotechnology GmbH											
Winicker Norimed GmbH											•
Zentrum für Humangenetik und Laboratoriumsdiagnostik									•		



8sens.biognostic GmbH

biognostic

Robert-Rössle-Straße 10 13125 Berlin

T +49 (30) 9489-2116 F +49 (30) 9489-2117 Employees: 12 ilka.renneberg@biognostic.de

www.biognostic.de

Founded: 2000

Target Discovery

Target Validation

Hit Identification

Lead Optimisation

O Preclinical Studies

O Clinical Trials

8sens.biognostic GmbH

- Development of Immunochromatographic Rapid Tests – complementing laboratoy analyses or even making them obsolete
- Easy access to fast growing point-of-care market – not only for ELISA-developers

Our application fields: healthcare: human, dental and veterinary medicine, food industry, drug control, environmental

8sens.biognostic has ample experience in transfering your know-how to lateral flow test strips. On request, we will develop the entire test for you – consumer-ready from research & development to production. Take advantage of our

know-how.

We offer:

- · realisation of complete R&D projects on demand
- · stages include:
 - · feasibility studies
 - test development
- · declaration of conformities
- · production of entire test systems
- · different sample matrices
- · CE-, ISO- and IVDR-compliant
- cost-efficient & transparent milestone dependent project work and payment schedules
- · certified production facilities in Berlin, Germany

ABX-CRO advanced pharmaceutical services



Blasewitzer Straße 78–80 01307 Dresden T +49 (351) 2144-40 F +49 (351) 2144-415 Founded: 2002 Employees: 80 info@abx-cro.com www2.abx-cro.com

- Target Discovery
- Target Validation
- O Hit Identification
- Lead Optimisation
- Preclinical Studies
- Clinical Trials

ABX-CRO is a globally operating clinical research organization with a strong focus on pre-clinical and clinical molecular imaging and molecular radiotherapy. Based on over 15 years of experience in diagnostic and therapeutic oncology, neurology and other disease areas, ABX-CRO provides you with unique opportunities to test your drug candidates in complex pre-clinical disease models which can be assessed quantitatively using molecular and functional imaging (PET, SPECT, CT, MRI).

We translate pre-clinical results into First in Man studies and support you with design and execution of efficient late stage clinical trials, minimizing your costs and time to marketing authorization. ABX-CRO makes translational medicine a visible reality.

Accelero® Bioanalytics GmbH

accelerō bioanalytics

Volmerstraße 9A Founded: 2011 12489 Berlin Employees: 9

T +49 (30) 610-910-307 service@accelero-bioanalytics.com

www.accelero-bioanalytics.com, www.binding-assay.com

Accelero Bioanalytics is a laboratory service provider:

- · Good Laboratory Practice (GLP) certified
- · Good Clinical Practice (GCP) compliant
- · Biosafety level 3** for potentially infectious material
- · Genetic engineering safety level 2 approved

Our expertise includes Advanced Therapy Medicinal Products (ATMP) like:

- · Living biotherapeutics (microbial cells, human mesenchymal cells, limbal stem cells, etc)
- · Adeno-associated viruses (AAV)
- · Adenovirus serotype 5 oncolytic viruses (replicative and non-replicative)

Benefit from our everyday practice and visit one of our GLP seminars, or contract us for an GLP audit at your site!

- O Target Discovery
- O Target Validation
- Hit Identification O Lead Optimisation
- Preclinical Studies
- Clinical Trials

acromion GmbH

Research Organisation.

Europaallee 27-29 Founded: 2002 20226 Frechen Employees: 47

T +49 (2234) 2037-370 info@acromion-gmbh.com F +49 (2234) 2037-379 www.acromion-gmbh.com

acromion GmbH is a German headquartered, privately owned, full-service, clinical Contract

Operating throughout Europe, our teams provide the full range of clinical research services for biotech, pharmaceutical, medical device and diagnostics industries.

Founded in Germany in 2002, our company now offers nearly two decades of successful clinical research across all stages of clinical drug development, starting at First-in-Man to postmarketing studies and registries. Our work has been successfully audited by numerous clients and inspected by competent authorities.

A good match: acromion is the right sized research partner that integrates professional expertise aiming at the most suitable trial design, plan and conduct. We can introduce the right team to fit your company's needs and the specifics of your project; skilled, experienced, flexible.

Full or part service: protocol development or validation, hands-on project management, site recruitment, study start-up including regulatory management in geographical Europe, clinical monitoring, data management, EDC, STDM, biostatistics, safety management and pharmacovigilance, medical writing (protocol, ICF, IB, IMPD, CSR, CTD, publications), site training, quality assurance.

acromion

- O Target Discovery
- O Target Validation
- Hit Identification Lead Optimisation
- O Preclinical Studies
- Clinical Trials

Alcedis GmbH

ALCEDIS

 Winchesterstraße 3
 Founded: 1992

 35394 Gießen
 Employees: 120

 T +49 (641) 94436-0
 info@alcedis.de

 F +49 (641) 94436-70
 www.alcedis.de

- O Target Discovery
- O Target Validation
- Hit Identification
- Lead Optimisation
- O Preclinical Studies
- Clinical Trials

Alcedis GmbH stands for long years of CRO experience and profound expertise in the conduct of clinical trials. One focal point distinguishing Alcedis is our innovative software AlcedisTRIAL that constitutes a centrepiece of the Alcedis trademark.

With our offices in Gießen, Hamburg and New York we offer a full service portfolio and successfully conduct phase (I), II–IV clinical studies as well as non-interventional studies in various indications on a global platform.

Classical CRO services provided are Scientific Consulting, Clinical Project Management, Monitoring, Medical Writing, Regulatory, Data Management, Pharmacovigilance and Biometrics.

Our module-based service concept adjusts itself flexibly to your project structure. Likewise individually adapted are our data entry and software systems.

Allied Clinical Management GmbH



Hamburger Straße 14 16341 Panketal T +49 (30) 240 4788-0 F +49 (30) 240 4788-19 Founded: 2004 Employees: n.a. info@allied-clinical.com

www.allied-clinical.com

Target Discovery

- Target Validation
- Hit Identification
- Lead Optimisation
- Preclinical Studies
- Clinical Trials

Since its founding in 2004, Allied Clinical Management GmbH has been conducting medical device and pharmaceutical product clinical trials ethically, reliably and efficiently.

A commitment to long term partnerships with sponsors enables it to deliver clinical data of superior and consistent quality.

As a member of the MEDIS RESEARCH GROUP, Allied Clinical Management provides the following services for prospective clinical trials:

- Planning and Designing of Translational Studies and Clinical Trials
- · Scientific Consulting
- · Trial Management

- · Monitoring and Site Management
- Ethics Committee and Competent Authority dossier preparation according to GCP, ISO and national and international regulations
- · Data Management
- Biostatistics
- · Medical Writing and Publication
- · Pharmacovigilance and Device Vigilance
- · Regulatory Affairs
- Authorized Representative for Companies outside the EU
- · Marketing Applications

AMP-Lab GmbH

Mendelstraße 11 Founded: 1998 48149 Münster Employees: 4 T +49 (6131) 26345-70 info@amplab.de F +49 (6131) 3354-22 www.amplab.de



AMP-Lab is an independent laboratory for applied biological research in physiology and biochemistry.

Our expertise and facilities meet special services and products, currently available on five different levels of physiology:

- · enzymes,
- · metabolism,
- · physiological liquids,
- · semen analysis
- · and angiogenesis.

We consult in individual questions on physiology. For solving your particular problem, time-limited research programs are offered on your request.

Our laboratory is fully equipped for physiological and biochemical analyses. Our close cooperation with institutes for physiological and biochemical research is a guarantee of our up-to-date knowledge and techniques.

- Target Discovery
- Target Validation
- Hit Identification
- O Lead Optimisation
- Preclinical Studies
- O Clinical Trials

AMS Advanced Medical Services

Am Exerzierplatz 2 Founded: 1997 68167 Mannheim Employees: 300 T +49 (621) 70095-100 ams@ams-europe.com

F +49 (621) 70095-140 www.ams-europe.com

AMS established itself as reliable service provider for Clinical Research and Sales Force Services. To realize your goals, we work to develop a common understanding of the objectives and the paths that will lead us to achieve them. We thus strive to align the perspective of our customers with the knowledge of our experts. Full support service in Clinical Research including post-marketing services with global reach: Whatever the task, you can have total confidence in AMS Clinical Research. The experience, solution-oriented and flexible thinking of AMS' teams will stand out from the crowd.

In close exchange with the HTA authorities, we are at the forefront of current developments

to bring your project to fruition. Our Team is characterized by the continuous interaction of experts in Medical Writing, Biostatistics and Public Health Economics. Based on our longterm experience in the fields of global clinical development, drug registration, benefit assessment, price negotiations and reimbursement, we make it our mission to implement your goals.

AMS offers field force solutions in DACH: building up and allocating field sales forces, filling vacancies via employee assignments and online certification courses.

Take advantage of our expertise and our enthusiasm for new challenges!



- Hit Identification
- Lead Optimisation

O Target Discovery

Target Validation

- O Preclinical Studies
- Clinical Trials

analyze & realize GmbH

 Waldseeweg 6
 Founded: 1993

 13467 Berlin
 Employees: 40

 T +49 (30) 4000-8100
 business@a-r.com

F +49 (30) 4000-8500 www.analyze-realize.com



- O Target Discovery
- O Target Validation
- Hit Identification
- Lead Optimisation
- Preclinical Studies
- Clinical Trials

analyze & realize - Your innovation experts in natural health products.

The company was founded in 2000 and offers consultancy and clinical research services to the consumer health and natural products sector. Our services are closely aligned with the current market situation for the respective products. Hence, our professional support is guided by international and national trends that are defined by regulations and consumer needs.

Clinical Research

Clients can profit from our experience in more than 300 clinical trials with natural health products and our in-depth expertise in the development of targeted study designs reflecting individual needs.

Consulting & Strategic Innovation

Our services range from regulatory consulting to product development for food and supplements (incl. novel food and health claim strategies) and as well for herbal drugs and substance-based medical devices.

MatchMaking

Our unique expertise and more than 20 years of international networking in the natural products industry allow us to identify relevant in- and out-licensing opportunities and assist in the selection of the optimal partners to grow our clients business.

Antiinfectives Intelligence GmbH

Von-Liebig-Straße 20 Founded: 2000 53359 Rheinbach Employees: 8

T +49 (2226) 908-911 info@antiinfectives-intelligence.de F +49 (2226) 908-918 www.antiinfectives-intelligence.de

- Target Discovery
- O Target Validation
- O Hit Identification
- Lead Optimisation
- Preclinical Studies
- O Clinical Trials

We carry out microbiological research: Microbiological safety:

- Testing of the efficacy of preservatives used in pharmaceuticalss
- Testing of the microbiological quality of medications with and without preservativess
- Testing of the microbiological safety of medicinal productss
- Investigation of the microbiological stability of products (shelf life) during simulation models In-vitro Activity of Antibiotics
- Determination of the in-vitro efficacy of antibiotics
- Determination of the pharmacodynamics of antibiotics in an in-vitro models

 Investigations of the development of the resistance of bacteria to antibiotics resistance surveillance studies

Antiinfectives Intelligence

- Planning, organization, carrying out and evaluation of resistance surveillance studies
- Preparation of final reports and publications of external resistance surveillance studies

ARTES Biotechnology GmbH

artes

Elisabeth-Selbert-Straße 9 Founded: 2002 40764 Langenfeld Employees: 22

T +49 (2173) 275 870 info@artes-biotechnology.com F +49 (2173) 275 8777 www.artes-biotechnology.com

ARTES Biotechnology is a biopharmaceutical contract research organization (CRO) that provides microbial cell line and process development for bio-pharmaceutical products. The company is a well-established partner for many of the biggest names in the industry, with more than 20 years of business experience, a track record of products developed for and marketed by clients as well as for safe, reliable and highly competitive microbial production platforms.

ARTES specializes in recombinant protein production, process and vaccine development, marketing the unique METAVAX® (dHepB-VLP) technology in combination with yeast expression.

In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization.

ARTES operates worldwide from its 850 m² S1 facilities in Langenfeld, Germany, from where it also supplies non-GMP bulk material (API) for activity and toxicity tests and technology transfer to cGMP facilities and scale-up support.

Further information from the ARTES Biotechnology website at: www.artes-biotechnology.com

- Target Discovery
- O Target Validation
- Hit Identification
- Lead OptimisationPreclinical Studies
- O Clinical Trials

ASCA GmbH Angewandte Synthesechemie Adlershof



 Magnusstr. 11
 Founded: 2000

 12489 Berlin
 Employees: 16

 T +49 (30) 6392-2070
 asca@asca-berlin.de

 F +49 (30) 6392-4103
 www.asca-berlin.de

ASCA provides the pharmaceutical industry, crop protection and biotech companies with a partner for the synthesis and optimisation of lead structures. We supply novel and practicable solutions for the development of new active structures, and check these on a laboratory scale.

ASCA offers an extension of our partners' preclinical research capacity. The cooperation is caracterized by close contact and regular progress reports.

Furthermore we are well experienced in the preparation of reference substances and labelled analytical standards.

Our catalogue comprises mor than 400 compounds and relevant metabolites.

Categories are:

- pesticides
- · API's
- · plastc additives like sun blockers
- mycotoxines
- · drug-like natural products.

We also offer custom syntheses.

- Target Discovery
- Target Validation
- Hit IdentificationLead Optimisation
- O Preclinical Studies
- O Clinical Trials

Assay.Works GmbH

assay.works

Am Biopark 11 93053 Regensburg T +49 (941) 2000-1240 F +49 (941) 2000-1241 Founded: 2016 Employees: 6

contact@assay.works www.assay.works

- Target Discovery
- Target Validation
- Hit Identification
- O Lead Optimisation
- Preclinical Studies
- O Clinical Trials

Assay.Works is a contract research organization (CRO) providing research services to pharmaceutical/biotech companies and academic organizations in form of fee-for-service work.

Our mission is to accelerate our partner's research programs by developing and executing predictive and scalable assays to quantify the bioactivity of novel chemical and biological entities. We combine scientific rigor with our domain expertise in laboratory automation, informatics, and industry best practices to turn challenging assays into quantitative, reproducible results.

Our service portfolio includes:

- · Assay Development
- High-Throughput Screening (HTS)
- Cell Line Engineering and Production of Cellular Reagents
- · Bioactivity Assessments
- · Quantitative Biology Applications

ATLAS Biolabs GmbH



Friedrichstraße 147 10117 Berlin T +49 (30) 3198966-0 F +49 (30) 3198966-19 Founded: 2006 Employees: 15

customer-support@atlas-biolabs.com

www.atlas-biolabs.com

Target Discovery

Target Validation

Hit IdentificationLead Optimisation

C Lead Optimisation

Preclinical Studies

Clinical Trials

ATLAS Biolabs is a leading European service provider of complex analyses in molecular genetics, including next generation sequencing, microarray analyses supplemented by high-level data analyses support and RNA/DNA isolation from biological specimens.

Founded in 2006 as a spin-off of the German Resource Center for Genomics and the Cologne Center for Genomics. Company's services are certified by Affymetrix, Agilent, and NimbleGen. Customers include academic institutions, pharmaceutical and biotechnological companies as well as clinicians and registered doctors.

It has great experience to manage large projects. We can guarantee GCP compliance, as our laboratory staff has been trained on GCP and we are following guidelines of the Medicines and Healthcare products Regulatory Agency (MHRA). ATLAS fulfills the requirements for design and manufacturing in vitro diagnostic medical devices according to ISO 13485:2012/AC:2012. Quality management is organized according to ISO 9001:2008.

Axolabs GmbH

LGC AXOLABS

Fritz-Hornschuch-Straße 9 95326 Kulmbach T +49 (9221) 8276-28115 F +49 (9221) 8276-299 Founded: 2000 Employees: 95 info@axolabs.com www.axolabs.com

Axolabs is the leading Custom Research Organization focused on the discovery and preclinical drug development in the field of oligonucleotide therapeutics and nucleic acid medicines.

With our world-leading know-how we provide high-end preclinical solutions and consultancy tailored to our clients' specific needs. Our products and services relating to oligonucleotides include manufacturing, analytics and detection, also including mRNAs, from biological matrices under the standards of GLP/GCP, lead identification, functional cell type-specific delivery, a variety of biological and pharmacological techniques, as well as release under GMP.

- Target Discovery
- Target Validation
- O Hit Identification
- Lead Optimisation
- Preclinical Studies
- O Clinical Trials

AZ Biopharm GmbH Berlin

Bitterfelder Straße 19 12681 Berlin T +49 (30) 93652-0 F +49 (30) 93652-200 Founded: 2002 Employees: 29 info@az-biopharm.de www.az-biopharm.de



Analytical Center Biopharm GmbH is a GLP and GMP certified testing facility (CRO) with many years of experience in bioanalytical and pharmaceutical testing of human and veterinary drugs.

We determine the identity, content and purity of active substances and drug products and perform residue analysis in edible farm animal tissues, stability testing and physicochemical analysis of intermediates according to the Chemicals Act. Under GLP and/or GCP we determine the drug concentration and, where applicable, their metabolites in biological matrix in bioequivalence-, pharmacokinetic-, bioavailability- and preclinical studies using state-of-the-art analytical techniques.

AZB is actively working on the development and validation of new, analytical methods that are required among others as part of an authorisation and registration obligation in the pharamceutical industry. Compliance with the applicable and valid guidelines (EMA, FDA, ICH, VICH, etc.) is a top priority in this process. Within bioanalysis, AZB develops and validates new methods for pharmaceutical active ingredients and their metabolites as well.

AZB is characterized by flexibility and innovativity and has been a reliable partner of the pharma industry for 25 years.

- Target Discovery
- Target Validation
- Hit IdentificationLead Optimisation
- C Lead Optimisation
- Preclinical Studies
- Clinical Trials

Biaffin GmbH & Co KG – Biomolecular Interaction Analysis

AVZ 2, Heinrich-Plett-Straße 40 34132 Kassel

T +49 (561) 8044 668 F +49 (561) 8044 665 Founded: 2001 Employees: 7 info@biaffin.de www.biaffin.com



- O Target Discovery
- Target Validation
- Hit Identification
- Lead Optimisation
- Preclinical Studies
- O Clinical Trials

Biaffin is an ISO 9001 certified company offering services in biomolecular interaction analysis with expertise and knowledge in application of biosensors based on surface plasmon resonance (SPR) to kinetically characterize any pair of interacting molecules in real-time. Well equipped with several SPR Biacore instruments Biaffin assures performance of projects in a professional and timely manner.

Biaffin's SPR services are applied in various stages of drug development like fragment-based and confirmatory, secondary screening, hit validation, lead optimization and ADME studies. In biopharmaceutical development Biaffin offers kinetic characterization, stability analyses and

batch to batch comparison of therapeutic antibodies, biologics and biosimilars. SPR studies on specificity, selectivity, mechanism of action and thermodynamics are performed as well.

Besides SPR services Biaffin offers biochemical assays based on microfluidic mobility shift technology (MMSA) and bioluminescence.

Bicoll GmbH

Am Klopferspitz 19 82152 Planegg/Martinsried T +49 (89) 820 106 30 F +49 (89) 529 178 Founded: 2000 Employees: 5 info@bicoll-group.com www.bicoll-group.com



- Target Discovery
- Target Validation
- Hit IdentificationLead Optimisation
- Lead Optimisation
- Preclinical Studies
- O Clinical Trials

Bicoll is an expert in field of plant small molecules backed up by a strong medicinal chemistry. Bicoll focuses on delivering breakthrough solutions in pharmaceuticals, cosmetics, nutraceuticals and agriculture.

Bicoll is an inventor of Bicoll Plant Profiles™, which provides the fastest and the most successful method from initial screening to the animal tests or products. Bicoll offers solutions from scientific gathered and carefully processed plant species with an outstanding knowledge in high tech natural product chemistry to validated experience in medicinal chemistry to any type of client: from big pharma to a small research group. The robust technology allows it to serve

biological screening approaches (whole cell, whole organism) as well as biochemical high-throughput-screening set-ups (e.g. protein-protein interaction with FRET-read-out).

With further innovative strategies supported by its proprietary in-house technology platform, BICOLL is able to rapidly select only the best leads with superior drug-like profiles for the further development cycles.

Bioassay GmbH



Im Neuenheimer Feld 515 69120 Heidelberg T +49 (6221) 43388-910

Founded: 2002 Employees: 25 info@bioassay-or

F +49 (6221) 43388-99

info@bioassay-online.de www.bioassay-online.de

Bioassay GmbH is an independent contract laboratory, specializing in the development, validation and routine performance of bioanalytical assays in the area of Pharmacology and Toxicology.

We carry out qualified analytical services on the sound basis of our GMP & GLP certification, which provides an excellent framework for successful projects and routine bioanalysis.

Bioassay GmbH is specialized in the development, validation and execution of biological assays within the framework of Development & Quality Control of pharmaceutical and chemical products.

Our portfolio contains 4 focus areas:

- · BioPharma Potency
- · BioPharma Efficacy
- · BioPharma Safety
- · Chemicals/Cosmetics Safety

In our in-vivo and in-vitro facilities we are running state-of-the-art-equipment and our analytical experts will welcome you to visit us in our laboratories located directly in the Heidelberg Technology Park (Germany).

- O Target Discovery
- O Target Validation
- Hit Identification
- Lead OptimisationPreclinical Studies
- O Clinical Trials

biometec GmbH



Walther-Rathenau-Straße 49a Founded: 1992
17489 Greifswald Employees: 2
T +49 (3834) 515-620 witt@biometec.de
F +49 (3834) 515-622 www.biometec.de

The company is engaged in the development, production and distribution of research products for infection biology especially CD14, LBP and antibodies. In addition biometec offers a variety of laboratory and immunbiological services for academic institutes as well as pharmaceutical and biotechnological companies.

Our service include Hybridoma development for new antibody producing cells, monoclonal antibody production, purification and labelling as well as contract research as cell culture investigations, animal models, cytokine research, microbiological investigations, immunological contract research, screening investigations for clinical studies, polyclonal antibody service and ELISA development.

- Target Discovery
- O Target Validation
- Hit IdentificationLead Optimisation
- O Preclinical Studies
- O Clinical Trials

Biosyntan

T +49 (30) 9489 3498

F +49 (30) 9489 3497

Robert-Rössle-Straße 10 Founded: 1997 13125 Berlin Employees: 6

> biosyntan@biosyntan.de www.biosyntan.de



O Target Discovery

O Target Validation

Hit Identification

Lead Optimisation

O Preclinical Studies

O Clinical Trials

BIOSYNTAN GmbH was founded in 1997 as a scientific service company, focused on custom synthesis of peptides. A rising interest of our costumers in modified peptides has prompted us to develop new methods for the manufacturing of such compounds.

As one of the leading specialists in the synthesis of linear and cyclic peptides with unusual residues (natural or artificial) and a multitude of modifications we can offer you an extensive range of services today.

Our core area is the manufacturing of fluorescently labeled peptides for assay development and the synthesis of posttranslational modified peptides.

BIOTREND CHEMIKALIEN GmbH

Eupener Straße 157 Founded: 1988 50935 Köln Employees: 14 T +49 (221) 94983-20 info@biotrend.com F +49 (221) 94983-25 www.biotrend.com



Target Discovery

Target Validation

Hit IdentificationLead Optimisation

Lead Optimisation

Preclinical Studies

O Clinical Trials

After more than a decade of experience in the sale and marketing of research products for "Life Science Research", Werner Hassler, Switzerland and Gunther Jaeger, Germany founded the Cologne based BIOTREND Chemikalien GmbH in May 1988.

BIOTREND was instigated in order to meet the growing demand from customers for an independent and technologically orientated distribution facility offering high quality, yet cost-effective products for biochemical, immunochemical and pharmaceutical research, offering Conjugation Service, Custom Antibody Production, Peptide Libraries and Peptide Syntheses, [1251] Iodination Service, [3H] Tritiation Service.

Carpegen GmbH

Mendelstraße 11 48149 Münster T +49 (251) 980 2320 F +49 (251) 980 2321

Founded: 2001 Employees: 8 info@carpegen.de www.carpegen.de

Carpegen is a provider of high quality molecular diagnostics. The company focuses on developing real-time PCR assays and point-of-care (POC) diagnostics for the diagnosis of specific infections and the detection of genetic biomarkers.

Carpegen has developed Carpegen® Perio Diagnostics, a powerful real-time PCR based system that sets new standards in microbiological periodontal diagnostics.

A main objective of Carpegen's research program is to develop and out-license POC/PCR systems for diverse applications in human and veterinary medicine, as well as in food/beverage and environmental analytics.

A joint R&D project related to the development of innovative analytics of water pathogens is currently being pursued with financial support of the German Federal Ministry for Economic Affairs and Energy.

- O Target Discovery
- O Target Validation
- O Hit Identification
- O Lead Optimisation Preclinical Studies
- Clinical Trials

CeGaT GmbH

Paul-Ehrlich-Straße 23 Founded: 2009 72076 Tübingen Employees: 170 T +49 (7071) 565 4455 info@cegat.de F +49 (7071) 565 4456 www.cegat.de



CeGaT is a global provider of genetic diagnostics and mutation-related disease analyses. Our laboratory is located in Tuebingen, Germany and is fully accredited with a focus on high quality results (CAP/CLIA and ISO 15189:2014).

Our diagnostics product portfolio includes diagnostic panels, single gene testing, exome diagnostics, deletion/duplication analyses, array-CGH, tumor diagnostics and many more.

Moreover, we provide a variety of sequencing services. These include not only the preparation of the samples using various automated platforms, but also Next-Generation Sequencing (NGS) on different platforms (NovaSeq and MiSeq).

We can provide additional data analysis options, with the choice to receive raw sequencing data through to processed and filtered variant call files.

- Target Discovery
- Target Validation
- Hit Identification Lead Optimisation
- Preclinical Studies
- Clinical Trials

Celares GmbH



 Building D80, Robert-Rössle-Straße 10
 Founded: 2003

 13125 Berlin
 Employees: 20

 T +49 (30) 9489 2350
 info@celares.com

 F +49 (30) 9489 2351
 www.celares.com

- O Target Discovery
- O Target Validation
- Hit Identification
- Lead Optimisation
- Preclinical Studies
- O Clinical Trials

The conjugation of drug molecules is an established tool for increasing tolerance, efficacy, half-life, or solubility of (bio)pharmaceuticals. Celares has an unique expertise in PEGylation/conjugation of (bio)molecules and offers customized solutions for conjugation of (bio) molecules as well as process development and contract manufacturing.

Our services include feasibility studies – investigation of conjugation strategies, ADC-strategies, screening of different conjugation reagents, preparation and characterization of drug-conjugate test samples – development services from scratch to the clinical phase – optimization of reaction conditions, development and validation

of purification and analytical methods, consistency runs, generation of reference standards, stability studies according to ICH Contract manufacturing of activated PEGs, PEG-drug conjugates and small molecule drugs – Proof-of-concept material, production of activated PEGs based on GMP, tailor-made PEGs or other polymers, such as block-copolymers, hyperbranched polyglycerols, among others.

Celares also offers surface modification technologies for diagnostic purposes.

cellasys GmbH



cellasys your partner in microphysiometry

- Target Discovery
- Target Validation
- Hit IdentificationLead Optimisation
- Lead Optimisation
- Preclinical Studies
- O Clinical Trials

cellasys delivers system solutions for microphysiometry. These include services such as contract research, research & development, and production & maintenance.

Furthermore we offer consulting services in the area of application development, data analysis and data interpretation.

The microphysiometric systems monitor different parameters directly from living cells. These parameters include extracellular acidification (pH), cellular respiration (pO₂) and morphology (impedance).

The measurement is label-free, parallel, continuous and in real-time. With our BioChip technology one can e.g. determine the efficacy of a drug outside of humans (or animals) directly on living cells.

CellServe GmbH



 Chariteplatz 1
 Founded: 1996

 10117 Berlin
 Employees: 1

 T +49 (30) 4505-13198
 gf@cellserve.de

 F +49 (30) 4505-13943
 www.cellserve.de

CellServe GmbH is a spin-off of Charité – University Medicine, Berlin-Brandenburg Center for Regenerative Medicine (BCRT).

CellServe GmbH is developing a cell therapy for the treatment of life-threatening chronic heart disease.

The cell product, consisting of Cardiacderived Adherent Proliferation Cells, shows excellent cardiac function improvement in preclinical studies, but also provides the practical prerequisites for the preparation of a commercial cell therapy. The study protocol for the clinical Phase I/II trial has been finalized and is approved by the responsible ethics committee of Berlin and Paul-Ehrlich Institute (PEI).

- O Target Discovery
- O Target Validation
- O Hit Identification
- Lead OptimisationPreclinical Studies
- Clinical Trials

CellTrend GmbH

Im BiotechnologieparkFounded: 199814943 LuckenwaldeEmployees: 7T +49 (3371) 6199 600info@celltrend.deF +49 (3371) 6199 604www.celltrend.de



CellTrend is an innovative certified (GMP, ISO 13485) biotech company. We offer the following technologies and services:

Cell culture assays for drug research (bioactivity assays):

- Screening
- · Lead optimization
- · drug development

Immunoassays

- Development of assays for new analytes, immunogenicity testing
- · Development of Companion Diagnostics

- Contract analytical service for preclinical and clinical samples
- Development, production and distribution of immunoassays for diagnostic and research

Consulting

- · External qualified person
- · Quality Management Systems
- \cdot GMP testing lab for bioanalytical methods

- Target Discovery
- Target Validation
- Hit IdentificationLead Optimisation
- Preclinical Studies
- O Clinical Trials

ChemCon GmbH

Good Manufacturing Partner

Engesserstraße 4b Founded: 1997
79108 Freiburg Employees: 100
T +49 (761) 5597 0 info@chemcon.com
F +49 (761) 5597 449 www.chemcon.com

- O Target Discovery
- O Target Validation
- Hit Identification
- O Lead Optimisation
- Preclinical Studies
- Clinical Trials

ChemCon is a GMP-compliant contract development and manufacturing organization (CDMO) and provider of analytical testing services. Customers worldwide use ChemCon's services to source high-quality APIs for clinical trials, registration and/or commercial applications.

ChemCon's FDA-inspected facilities are optimized for the chemical production of small to medium quantities (grams to a few hundred kilograms annual supply) of GMP material for human use. With multidisciplinary chemical expertise, ChemCon meets your individual demands for small-molecule organic APIs, inorganic salts and complexes, or polymers, including highly potent or controlled substances.

Besides APIs, ChemCon also offers the synthesis of other compounds, such as advanced excipients, injectable-grade trace elements, delivery agents, or reference standards to your specifications.

ChemCon's high-quality/small-to-medium-quantity niche can be particularly interesting for applications in orphan diseases, oncology, emergency care, transfection (synthesis of the polymer), and other specialty applications. Comprehensive in-house analytics, stability studies, documentation, and regulatory support complete our services.

ChemCon looks back on an outstanding inspection history both by the FDA and European health authorities.

Chimera Biotec GmbH



Emil-Figge-Straße 76a Founded: 2000 44227 Dortmund Employees: 25

T +49 (231) 9742 840 info@chimera-biotec.com F +49 (231) 9742 844 www.chimera-biotec.com

Target Discovery

- Target Validation
- Hit IdentificationLead Optimisation
- C Lead Optimisation
- Preclinical Studies
- Clinical Trials

Chimera Biotec provides ultra sensitive GLP/GCP bioanalytical support for all phases of drug discovery and development. For 20 years, we have specialized in supporting drug development programs with highest demands on bioanalytical quality.

Our long standing know how in beyond ELISA sensitive immunoassays enables us to make the most out of any immunoassay platform.

It is our goal to ensure your success in all phases of drug development providing highly sensitive, accurate and reliable bioanalysis data on-time. Beside classical ELISA and other platforms we combine immunoassays with exponential PCR read-out in Imperacer, our proprietary Immuno-PCR platform.

We can support studies where other CROs fail. Our research team is highly experienced in the development and validation of ultra sensitive immunoassays.

All our services are conducted under strict quality regime and bioanalytical sample testing is available for all needed regulatory demands, up to full GLP-compliant support.

CIRES cell & immune research services



Universitätsstraße 136 Founded: 2001 44799 Bochum Employees: 3

T +49 (234) 93696536 frank.w.falkenberg@cires.de

F +49 (234) 93696538 www.cires.de

CIRES is a small Contract Research Company, specialized on:

 generation of murine and rat Hybridomas, We use special immunization procedures to get more monoclonal antibodies with higher specificities.

One of our specialities is that we also get highly specific monoclonal antibodies against human antigens that show similarities to the corresponding murine antigens.

2. mass production of monoclonal antibodies by bioreactor technology odf hybridoma cells

- 3. isolation of monoclonal IgG and IgM antibodies by affinity chromatography or by DEAE anion exchange chromatography
- 4. testing of adjuvants and immune stimulating agents
- application of innovative Cytokine-depot adjuvants developed by CIRES for various vaccines
- 6. pre-clinical vaccine trials in mice.

- Target Discovery
- O Target Validation
- O Hit Identification
- Lead OptimisationPreclinical Studies
- O Clinical Trials

CONET GmbH – Clinical Operations Network



Amselstraße 25 Founded: 1998
68307 Mannheim Employees: 20
T +49 (621) 789 7000 info@conet-gmbh.de
F +49 (621) 789 7010 www.conet-gmbh.de

CONET - Clinical Operations NETwork Your European Partner in Clinical Research

CONET's Special Services: CONET is specialised on immediate support for sponsors in case of challenging situations emerge:

- Any concern about the performance of a clinical trial?
- · Any need to ensure clinical research data integrity?
- Any need for resuce Monitoring in order to put the trial back on track before it might be too late?

In all these situations CONET is your preferred partner to handle necessary activities like rescuemonitoring, oversight- or co-monitoring, inspection readiness with expertise and extensive experience. CONET's Quality Philosophy is driven by the

goal to provide Sponsors with the highest quality servies. This committment is rooted in the corporate value and is essential for CONET's success.

CONET GmbH, Clinical Operations Network, is a well established full service Contract Reserach Organization (CRO), headquartered in Mannheim Germany. Since 1998 CONET operates with network partners in Europe, US and Israel. CONET offers flexible and customized solutions for clinical Trials Phase I–IV, pediatric trials, NIS, IITs and clinical trials for medical devices for sponsors located in EU, US and Israel.

For more information please contact us or see www.conet-gmbh.de.

- Target Discovery
- Target ValidationHit Identification
- O Lead Optimisation
- O Preclinical Studies
- Clinical Trials

Conreso GmbH

CONTESO

Finest Quality in Research.

Neuhauser Straße 47 80331 München T +49 (89) 2366-500 F +49 (89) 2366-5050 Founded: 1990 Employees: 20 info@conreso.com www.conreso.com

- O Target Discovery
- O Target Validation
- O Hit Identification
- O Lead Optimisation
- O Preclinical Studies
- Clinical Trials

Conreso, established in 1990, BVMA member, offers a wide range of medical and clinical research services, from phase II to late phase, epidemiological and non-interventional studies as well as other types of medica data collections.

Conreso shows an impressive record of successful and significant contributions to important new product licenses. Having recruited more than 30,000 patients between 0 and 17 years of age proves the company's unique expertise in pediatric trials.

Further areas of particular expertise are oncological and vaccine studies. Quality and service of Conreso are awarded by a constant repeat business rate of 90%.

The Conreso department of veterinary medicine provides all types of veterinary studies and data collections.

Conreso has the permanent permission for providing temporary workers.

Coriolis Pharma Research GmbH



Fraunhoferstraße 18 b 82152 Martinsried T +49 (89) 5424498-0 F +49 (89) 5424498-22 Founded: 2008 Employees: 120 info@coriolis-pharma.com

www.coriolis-pharma.com

Target Discovery

- Target Validation
- Hit IdentificationLead Optimisation
- Lead Optimisation
- Preclinical Studies
- O Clinical Trials

Coriolis is a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs including proteins, peptides, monoclonal antibodies, RNA/DNA, virus-like particles, vaccines, ATMPs and GMOs (up to Biosafety Level S2).

Coriolis is specialized in the provision of:

- · Formulation development services for liquid and lyophilized products including BSL1 and BSL2
- \cdot Pre-formulation and candidate selection \cdot Early stage formulation development \cdot Late phase formulation development \cdot Lyophilization process development \cdot Lyophilization cycle optimization
- · Scale-up and transfer studies · Developability/

manufacturability assessment · Support in container closure system selection · In-use stability studies · Stability testing including forced degradation studies · R&D and cGMP-compliant contract analytical services · Orthogonal analysis of subvisible aggregates and particles · Testing of BSL1 and BSL2 GMO material · Polysorbate analytics · Biosimilarity studies · Outstanding scientific expertise

Our mission "Formulation Innovation": combination of technologies, knowledge and experience to add substantial financial value to our customer's projects by generating IP and supporting patent life cycle management in later phases.

CROLLL GmbH



 Wörnitzstraße 115a
 Founded: 1998

 90449 Nürnberg
 Employees: 38

 T +49 (911) 252688 0
 info@crolll.de

 F +49 (911) 252688 40
 www.CROLLL.de

CROLLL, founded in 1998, is a full service CRO offering design, conduct, monitoring and analysis of clinical trials in cooperation with pharmaceutical and medical devices industry, universities and physicians. Our team of highly qualified employees with long-term experience in clinical research is focused on the rapid and straightforward accomplishment of complete or partial solutions for clinical trials as well as NIS and other research projects. 20 successful years are based on our philosophy: individual - fast - flexible. We focus on a very personalized service tailored to the individual needs for the efficient conduct of all projects. Our excellent quality of work is based on the personal commitment and motivation of our employees in order to meet the ambitious timelines of our clients. Up to now more than

800 projects have been completed successfully. Samples of our services are:

- · Project management
- · Trial coordination
- Monitoring
- Co-monitoring/auditing
- · Regulatory affairs
- · Medical Writing
- Preparation of DSURs MedDRA and ATS/DDD coding
- · Contract management
- Preparation of scientific publications, presentations and posters
- · Literature research
- Data management, eCRF and biometric services in cooperation with vendors
- Individual projects and challenges are welcome especially

- Target Discovery
- O Target Validation
- O Hit Identification
- Lead OptimisationPreclinical Studies
- Clinical Trials

CRS Clinical Research Services Andernach GmbH



Rennweg 72 Founded: 2006, foundation of legacy up to 1977

56626 Andernach Employees: 250

T +49 (30) 859949 401 volker.menschik@crs-group.de

F +49 (30) 859949 222 www.crs-group.de

CRS is one of the leading Early Phase CROs in Europe with a broad expertise in clinical development from First in Man (FIM) to Proof of Concept (POC) studies in various patient populations.

With a track record of more than 2,000 successfully completed trials in more than 40 years of experience, CRS contributed to the development and successful registration of numerous drugs in various therapeutic indications. Operating four Research units located in the main metropolitan areas of Germany, CRS has reliable access to a huge number of healthy volunteers and special patient populations.

Furthermore, a broad network of reliable partners generates guaranteed access to patient areas, especially in cardiometabolic diseases, as well as renal & hepatic impairment.

The outstanding quality of CRS's services is regularly confirmed by sponsor feedback, audits and authority inspections. Clients from various sectors of the healthcare industry (ranging from large and small pharmaceutical & biotech companies to developers of medical devices, nutritionals and cosmetics) benefit from the comprehensive service portfolio offered by CRS.

- Target Discovery
- Target ValidationHit Identification
- Lead Optimisation
- Preclinical Studies
- Clinical Trials

CTC North GmbH & Co. KG



Martinistraße 64 20251 Hamburg T +49 (40) 5247-190

Founded: 2006 Employees: 70 info@ctc-north.com www.ctc-north.com

- O Target Discovery
- O Target Validation
- Hit Identification
- Lead Optimisation
- Preclinical Studies
- Clinical Trials

Clinical Trial Center North (CTC North) is an independent full service CRO located on the campus of the University Medical Center Hamburg-Eppendorf (UKE) – a perfect position to provide services in clinical research and development and being an ideal partner for the pharmaceutical, biotech and medical device industry.

CTC North operates a state of the art Phase I unit with 35 beds (thereof 10 beds with intensive monitoring capabilities) plus 15 PSG beds for sleep studies, and conducts Phase I clinical trials from "first-in-man" to "proof-of-concept" as well as phase II and III projects with 70+ highly qualified medical, scientific and regulatory employees.

CTC North stands for complete clinical trial management complying with a competent and fair feasibility assessment as well as a professional recruitment service (healthy trial volunteers or patients in particular indications).

We offer advice and consulting services in the field of clinical research, particularly in the conduct of clinical trials. Regulatory submissions, monitoring, data management, PK/statistics and medical writing complete our full service approach.

Cube Biotech GmbH



Alfred-Nobel-Straße 10 40789 Monheim T +49 (2173) 99373 0 F +49 (2173) 99373 99

Employees: 15 contact@cube-biotech.com www.cube-biotech.com

Founded: 2012

Target Discovery

- Target Validation
- O Hit Identification
- Lead Optimisation
- Preclinical Studies
- O Clinical Trials

Cube Biotech is a privately-held company based in Monheim, Germany, with a fully-owned subsidiary in Wayne, PA, USA.

Cube Biotech was founded in 2012 by a group of experts in membrane protein biology and organic chemistry. With more than 50 years of experience shared among us, we provide:

- Excellence in membrane protein expression, purification, stabilization, and crystallization
- Expertise in synthesis of standard and tailormade affinity matrices
- · High-quality products at reasonable pricing

We offer the full range or single packages of membrane protein service from cloning to structure determination, and are building long-term partnerships to pharmaceutical, biotech, and academic organizations.

We produce most of our service consumables at our facilities in Germany, and sell these quality products at reasonable pricing. In addition, we have partnerships with renowned suppliers and are looking for OEM oppertunities from ml to hundreds of liter scale. Whatever you find on our website follows the principle: "we use what we sell, and we sell what we use"!

Because we use our own products on a daily basis, we are constantly optimizing our products, services and application protocols.

Dr. Notghi Contract Research GmbH



DR.REGENOLD

Beuthstraße 7 Founded: 1999 10117 Berlin Employees: n.a. T +49 (30) 206 225-0 contact@notghi.com F +49 (30) 206 225-100 www.notghi.com

Dr. Notghi Contract Research GmbH is an established, independent German contract research organization headquartered in the heart of Berlin.

Since 20 years it has been on client's behalf responsible for the development and safety of pharmaceuticals as well as approval of medicinal products and devices.

Dr. Notghi Contract Research GmbH is a qualified and flexible service provider for clinical trials, clinical evaluations as well as approval of pharmaceuticals and medical devices.

Our high standard of quality and good team spirit have always been rewarded by our clients with the contracts, projects and studies for the development, safety and approval of pharmaceuticals and medical devices.

The Dr. Notghi Academy as a part of the CRO was founded ten years ago to train qualified experts for clinical research and pharmacovigilance. The training programs are targeted to natural scientists, pharmacists and physicians, who are interested in clinical research.

We are your best partner in clinical studies and safety vigilance for pharmaceuticals and medical devices, as well as clinical evaluation of medical devices. Dr. Notghi Contract Research GmbH stands for quality, experience and competence.

- O Target Discovery
- O Target Validation
- Hit Identification
- O Lead Optimisation O Preclinical Studies
- Clinical Trials

Dr. Regenold GmbH



Regulatory requirements for the development, manufacturing, marketing authorization and subsequent monitoring of biologics must be integrated within the complex biological and medical context. Consequently, it is critical to link scientific and regulatory knowledge at a very early stage in the development of biologics.

Our team includes biologists, biotechnologists, chemists, pharmacists, medical doctors and regulatory specialists. We have been supporting the development and regulatory affairs of new biological entities, biosimilars and Advanced Therapy Medicinal Products (ATMPs) for over ten years. If necessary our in-house team can be complemented by experienced experts within

our network. Based upon your requirement we assemble a project team with the specific expertise to deliver an optimal solution tailored to the challenges of each complex biologic product.

- O Target Discovery
- Target Validation
- Hit Identification Lead Optimisation
- Preclinical Studies
- Clinical Trials

emovis GmbH

 Wilmersdorfer Straße 79
 Founded: 2001

 10629 Berlin
 Employees: 50

 T +49 (30) 3101-3610
 info@emovis.de

 F +49 (30) 3101-3633
 www.emovis.de



ENDOTHERM
LIFE SCIENCE MOLECULES

- O Target Discovery
- Target Validation
- O Hit Identification
- Lead Optimisation
- O Preclinical Studies
- Clinical Trials

emovis has four different types of services to offer for Sponsors and CROs:

Dedicated Research Site

Located in Berlin. Outpatient studies phases II-III. High Recruiter. HIgh Data Quality. Founded in 2001. Experience in more than 120 indications. Special Area of Interest: Psychiatric Indications. (www.emovis.de)

Patient Ward/Sleep Lab

3 beds dedicated to Clincial Research. Full Polysomnographic Equipment. Phase I studies in Patients, specifically in CNS indications. (www.emovis.de)

Home Care Visits in Clinical Trials

Offering homecare visits in Clinical Trials all over Europe. (www.emovis-homecarevisits.de)

Subsidary Camovis GmbH

Offering Site Support by Flying Study Nurses. (www.camovis.de)

ENDOTHERM GmbH

Science-Park II Founded: 1999
66123 Saarbrücken Employees: n.a.
T +49 (681) 3946 7570 info@endotherm.de
F +49 (681) 3946 7571 www.endotherm-lsm.com



- Target Validation
- Hit IdentificationLead Optimisation
- Lead Optimisation
- Preclinical Studies
- O Clinical Trials

Serving as a contract research organization (CRO), Endotherm Life Science Molecules is a provider of medicinally relevant compounds for the development of novel small molecule drugs and biomarkers for the development of diagnostic devices. Particularly, the company provides medicinal chemistry support for the discovery of new drugs to address unmet medical needs.

According to rational considerations and including computer assisted tools, focused compound libraries and single compounds for hit-finding, hit-to-lead studies and lead optimizations are designed and synthesized.

Additionally, 3,500 "inhouse-made" research chemicals can be selected from a continuously updated catalogue. Finally, the company has established a technology platform for the synthesis of complex chiral natural products, such as Vitamin D derivatives, in turn to be used for assay design, as compound libraries for screening, references, building blocks or for process research purposes.

Evotec SE

Essener Bogen 7 Founded: 1993 22419 Hamburg Employees: 2,800 T +49 (40) 56081-0 info@evotec.com F +49 (40) 56081-222 www.evotec.com



Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists.

We operate worldwide and our more than 2,800 employees provide the highest quality stand-alone and integrated drug discovery and development solutions.

We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate).

Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others.

- Target Discovery
- Target Validation
- Hit Identification
- Lead Optimisation
- Preclinical Studies
- O Clinical Trials

eXcorLab GmbH

Industrie Center Obernburg Founded: 2005 63784 Obernburg **Employees: 13** T +49 (6022) 81-2867 info@excorlab.de F +49 (6022) 81-2676 www.excorlab.com

eXcorLab GmbH was founded in 1983 as a biomedical laboratory within Akzo Nobel. Since 2005 the laboratory is an independent small and medium enterprise (SME), specialized on R&D contract research (CRO). The laboratory is accredited according to ISO 17025 which confirms the competence in our area of work and the application of a strict quality management system.

eXcorLab is performing ex vivo, animal and clinical studies of compounds, biomaterials or medical devices in contact with freshly donated human blood, primary tissue (cells) or cell lines. We assess membranes and equipment for hemodialysis and blood oxygenation, dialyzers, hemofilters, adsorbers, blood lines, catheters,

oxygenators, bone cements, wound dressings and (metal) implants in terms of e.g. performance, hemocompatibility and cytotoxicity (e.g. ISO 10993).

eXcorLab GmbH accompanies the development of medical devices (e.g. dialysis and oxygenation membranes, hemodialyzers, plasma separators, oxygenators), and biomaterials (e.g. bone cements). We strive to provide relevant (in vitro) models for application of products in life sciences.

Our accreditation is recognized worldwide in more than 60 countries (including countries within the EU, USA and Japan) based on the so called ILAC arrangement.

- ∈**X**cor**Lab**
- O Target Discovery
- Target Validation
- Hit Identification Lead Optimisation
- Preclinical Studies
- Clinical Trials

Experimentelle Pharmakologie & Onkologie Berlin-Buch GmbH



Robert-Rössle-Straße 10 Founded: 1997
13125 Berlin Employees: 45

T +49 (30) 9489 4440 info@epo-berlin.com F +49 (30) 9489 4441 www.epo-berlin.com

- Target Discovery
- Target Validation
- Hit Identification
- Lead Optimisation
- Preclinical Studies
- O Clinical Trials

EPO Berlin-Buch GmbH is one of Germanys leading contract research organization (CRO) that has specialized in:

Cancer Research Service

Providing tailored basic and translational research models to support drug development, starting from target validation and compound screening, and ending with integrational in vivo studies addressing pharmacology, pharmacokinetics, biomarkers, and tolerability.

Translational Research Service

Translational research in oncology from the perspective of the drug developer should provide the simple answer: "who is the right patient for my new drug", whereas the oncologist is interested in: "which is the right drug for my patient". EPO has developed large panels of tumor models providing efficient tools for preclinical drug development accelerating the initiation of clinical studies.

Personalized Medicine Service

Experimental cancer models are used to support and personalize the selection of the most appropriate drug treatment for the patient.

FGK Clinical Research GmbH





- Target Discovery
- Target Validation
- O Hit Identification
- Lead Optimisation
- O Preclinical Studies
- Clinical Trials

FGK Clinical Research GmbH is a Europe-based full service Contract Research Organization with offices in Germany (HQ), Poland, Czech Republic and Hungary. We provide full service for Phase I–IV clinical studies.

Our international client base includes biotechnology, medical device, and pharmaceutical companies. Main areas of expertise are oncology, CNS, dermatology and all major areas of internal medicine.

FGK has the right size to handle multi-country, multi-center studies with hundreds of patients or single country studies with a few patients, but is still small enough to guarantee a personal service to the sponsor. With our over 130 highly qualified medical, scientific and regulatory experts, we have all the knowledge and experience necessary to succeed in Europe and can guide you through the clinical trial process, from planning and approval to the final report.

FGK Clinical Research has two daughter companies: FGK Pharmacovigilance and FGK Representative Service, enabling us to offer our clients pharmacovigilance services including services of QPPV and PMSF management as well as legal representation for non- European customers conducting clinical studies or seeking marketing authorisation within the EU/EEA.

Formula GmbH

formula.

Pharmazeutische und chemische Entwicklungsgesellschaft mbH

Goerzallee 305 b Founded: 1995 14167 Berlin Employees: 10

T +49 (30) 7511054 info@formula-pharma.de F +49 (30) 75702408 www.formula-pharma.de

Formula GmbH was founded as a highly innovative company focussing on the development of medicinal products. Today, the development of medicinal products is a core business segment of Formula GmbH with the objectives of formulation of solid, semi-solid, liquid and injectable medicinal products. This also includes the development of lyophilizates, liposomes, infusible emulsions and sophisticated solid formulations, e.g. Multiple Unit Pellet Systems (MUPS).

In 2005, Formula GmbH was granted a manufacturing license for manufacturing clinical supplies regarding packaging, labelling, blinding, testing and release of solid, semi-solid and liquid formulations for non-sterile products.

In recent years, the manufacturing license has been constantly expanded and adapted to the needs of our customers. The manufacturing authorization and corresponding GMP certificate of Formula GmbH were successfully extended by the primary and secondary packaging of market goods, their quality control and market release.

Galenical development is always successful if analytical development and validation of analytical methods as well as stability testing are run in parallel. Therefore, our GMP-lab is instrumentally equipped to provide the required analytical services."

- Target Discovery
- O Target Validation
- O Hit Identification
- Lead Optimisation
- O Preclinical Studies
- Clinical Trials

GALAB Technologies GmbH - GALAB Laboratories GmbH



 Am Schleusengraben 7
 Founded: 1992

 21029 Hamburg
 Employees: 160

 T +49 (40) 368077 400
 kuballa@galab.de

 F +49 (40) 368077 401
 www.galab.de

GALAB is a company with core competences in analysis and separation technology.

GALAB offers analytical services, contract research services and proprietary tools (AffiSep, AffiSpin, GlycoCleave) for the Health Care, Food and Biopharmaceutical Industry. After more than 20 years of experience in business and a continuous improvement and extension of our competences GALAB has today acquired an outstanding market position.

We offer products for the following fields of application:

- Glycosciences
- · Oligosaccharides

- · Immobilized enzymes
- · Affinity Chromatography
- · Plant lectins
- · Biotin conjugates
- Assays
- · Customized products

Our special attention is addressed to product quality and product safety that we achieve by continuous improvement and scientific research.

A sophisticated in-house quality assurance system, the monitoring of our products and techniques, and an extensive documentation guarantee a highest degree of reproducibility and reliability.

- Target Discovery
- Target Validation
- Hit IdentificationLead Optimisation
- O Preclinical Studies
- O Clinical Trials

GBA Group Pharma – GBA Pharma Labs

CBAGROUP PHARMA

Fraunhoferstraße 11a Founded: 1978 81252 Martinsried Employees: 160

T +49 (89) 899 229-0 info@gba-pharma.com F +49 (89) 857 789-9 www.gba-pharma.com

- Target Discovery
- O Target Validation
- Hit Identification
- Lead Optimisation
- Preclinical Studies
- Clinical Trials

GBA GROUP PHARMA - Your Experts for Pharmaceutical Analytics and Solutions.

With a wide range of services, GBA GROUP PHARMA offers individual support throughout all stages of pharmaceutical product life cycle – from early lead optimization and early preclinical stage to global clinical studies, regulatory, marketing authorization, PPV and QP batch release testing in addition to the logistics of commercials.

GBA GROUP PHARMA is a leading provider for analytical and consulting services worldwide with six sites under one roof

The GBA PHARMA LABS run three GMP-certified and FDA-inspected sites in Germany with more

than 160 highly qualified employees and over 4,500m² of lab space.

Three more sites under the GBA GROUP PHAR-MA roof are represented by ABF Pharmaceutical Services (Vienna, Austria) providing Clinical Trial Supply Management, LKF (Kiel, Germany) offering Central Laboratory Services, as well as Pharmacelsus (Saarbruecken, Germany) providing Preclinical Drug Discovery and Development Testing incl. In-Vitro GLP/non-GLP Bioanalysis.

With a long-term expertise of over 30 years in the pharmaceutical business, GBA PHARMA LABS provide fast, flexible, and customer-oriented solutions.

GKM Gesellschaft für Therapieforschung mbH



Lessingstraße 14 Founded: 1981 80336 München Employees: 85

T +49 (89) 209120-0 mail@gkm-therapieforschung.de F +49 (89) 209120-30 www.gkm-therapieforschung.de

Target Discovery

- Target Validation
- O Hit Identification
- Lead Optimisation
- O Preclinical Studies
- Clinical Trials

GKM is an independent, family-owned contract research organization (CRO). We provide a comprehensive portfolio of services for the pharmaceutical industry, manufacturers of medical devices and academia.

With more than 38 years of expierence in the CRO business, GKM has completed over 900 clinical research projects, including national and international clinical trials as well as non-interventional studies, involving approximately 1.5 million patients across various indications.

GKM cooperates with more than 90 freelance clinical research associates (CRAs) throughout Germany, Austria and Switzerland and has established long-term successful co-operations with partner CROs world-wide.

The GKM team is highly experienced and knowledgeable in scientific, organisational and administrative matters of clinical research.

As a mid-sized CRO, we are able to respond rapidly, efficiently and flexibly to your unique needs, corporate policies and processes at every stage of your project.

glyXera GmbH

Brenneckestrasse 20 – ZENIT 39120 Magdeburg T +49 (391) 6117 -51 F +49 (391) 6117-255 Founded: 2011 Employees: 15 info@glyxera.com www.glyxera.com



glyXera is specialist provider of high-performance glycoanalysis, with products and services customizable to meet specific customer demands through using cutting edge methods and tools.

Our clients include the world's leading pharmaceutical, biotechnology and food companies.

We provide fast and reliable glycoanalysis utilizing cutting edge systems with superior performance and capacity, are the exclusive provider of glyXbox, a high-performance glycoanalysis system, and were awarded with the Innovation Price of the bioregions Germany, therefore.

We offer our clients sophisticated technology platforms and our expertise with respect to glycoanalytical products & services, tailored to the specific needs of academia, clinics, pharmaceutical and food industries.

We guide you for better decisions and help you to perform better and faster during discovery phase, R&D, (clinical) trials and approval of your innovative products (biopharmaceuticals, vaccines, food additives, functional food, etc.), and QA/QC in your production stages. Standard operating procedures (SOP) and a comprehensive quality management system ensure reproducible analyses on highest levels and guarantees transparency through all processes.

- Target Discovery
- Target Validation
- Hit Identification
- Lead OptimisationPreclinical Studies
- Clinical Trials

Health Research Services GmbH

 Hofäckerstraße 14
 Founded: 2000

 76698 Ubstadt-Weiher
 Employees: n.a.

 T +49 (7253) 9579-477
 germany@h-r-s.biz

 F +49 (7253) 9579-480
 www.h-r-s.biz

Health Research Services (HRS) Ltd, run offices in UK, Germany, Moscow, Kiev and Warsaw.

HRS GmbH is an independent contract research organisation offering specialist services in the areas of Consulting, Scientific Drug Research & Development, Project Management, Clinical Monitoring, Medical Writing, Biostatistics and Regulatory Affairs.

HRS provides expert services to turn basic research on promising new drug candidates into marketed medications.

Service Provider for Pharmaceuticals and Nutrition Science so both the innovative area of

personalized Health Medicine and therapeutic diet and food.

Consulting and Project Management in all stages of drug development and Product Life Cycle.

Medical Writing

The HRS medical writers are excellently trained medical or scientific experts.

Biostatistical consultancy.

Regulatory Affairs – for Clinicals, Herbals and Dietary Supplements – in America, Asia, Australia, Africa, Europe or UAE.

- HEALTH RESEARCH SERVICES
- O Target Discovery
- Target ValidationHit Identification
- O Lead Optimisation
- O Preclinical Studies
- Clinical Trials

Heidelberg Pharma AG

Schriesheimer Straße 101 Founded: 2004
68526 Ladenburg Employees: 70
T +49 (6203) 1009-0 info@hdpharma.com

F +49 (6203) 1009-19 www.heidelberg-pharma.com



- O Target Discovery
- Target Validation
- Hit Identification
- Lead Optimisation
- Preclinical Studies
- O Clinical Trials

Heidelberg Pharma is a biopharmaceutical company and specialized in oncology and Antibody Targeted Amanitin Conjugates (ATACs) and also offers preclinical research services. The ATAC technology is a completely new treatment approach for cancer therapy based on the unique biological mode of action of the toxin Amanitin and coupling it to tumor-specific antibodies. It works by inhibiting RNA polymerase II, which results in programmed cell death (apoptosis). RNA polymerase inhibition is a novel principle in cancer therapy and offers the possibility of breaking drug resistance and destroying dormant tumor cells.

As part of a hybrid business model, the Company grants licenses to its ATAC technology for

application to antibodies provided by customers. It also provides its partners technological support in the manufacture and purification of the conjugates, production and delivery of the compound, as well as necessary preclinical research.

In addition to collaborating with partners, Heidelberg Pharma is increasingly focused on developing its own therapeutic ATAC pipeline.

The company has the expertise and infrastructure for in vivo pharmacology and bioanalytics and offers preclinical research services outside of ATAC technology for cancer, inflammatory and autoimmune diseases.

ICCR-Roßdorf GmbH

In den Leppsteinwiesen 19 64380 Roßdorf T +49 (6154) 8070 F +49 (6154) 83399 Founded: 1999 Employees: n.a. info@iccr-rossdorf.de www.iccr-rossdorf.de



- Target Validation
- O Hit Identification
- Lead Optimisation
- Preclinical Studies
- O Clinical Trials

The Institute for Competent Contract Research Rossdorf offers experimental toxicological expertise since more than 3 decades.

Our main business is the investigation of the genotoxicological potency of pharmaceuticals, agrochemicals, cosmetics and chemicals. However, several additional disciplines of toxicology, mainly in vitro methods, are also in our portfolio (e.g. skin/eye irritation and corrosion, cytotoxicity, sensitisation testing).

For customers from the medical device business we offer modified protocols using extracts in accordance to ISO 10993-1. Almost all toxicological studies are performed under GLP in accordance to OECD Guidelines.

ICCR (C ROBDORF

In addition, batch release testing of drugs under GMP has been performed since more than 10 years.

Immundiagnostik AG

Stubenwald-Allee 8a Founded: 1986 64625 Bensheim Employees: 109

T +49 (6251) 70190-0 info@immundiagnostik.com F +49 (6251) 849430 www.immundiagnostik.com



Immundiagnostik AG develops and produces innovative immunological tests (ELISA, EIA) and other analytical detection methods such as HPLC, LC-MS/MS and PCR) for routine and research in medicine. The aim is to provide high quality, innovative and effective tools for the prevention, differential diagnosis and treatment monitoring. Focus is on gastroenterology / nutrition, cardiovascular / kidney, bone metabolism, oxidative stress, complementary medicine / preventive medicine, clinical immunology.

The product portfolio is complemented by a wide range of antigens and antibodies for research purposes. Business connections exist to clinical diagnostic laboratories and academic research institutions in the form of contract services, especially for the conduct of clinical trials. Collaborations with the pharmaceutical industry and memberships in scientific societies form the basis for a successful business development.

IDK owns more than 35 patents in Europe, the US, Japan, Canada, and Australia,is certified according to DIN EN ISO 13485 and fulfills the requirements of the German Medical Product Law (MPG) and the EU IVD Regulations (98/79 EG).

- O Target Discovery
- Target Validation
- Hit IdentificationLead Optimisation
- O Preclinical Studies
- O Clinical Trials

INFAI GmbH

Gottfried-Hagen-Straße 60–62 Founded: 1988 51105 Köln Employees: 20 T +49 (221) 88044-3 mail@infai.de F +49 (221) 88044-55 www.infai.de

INFAI is at the leading edge in the transfer of advanced analytical technology into medical diagnostics and the development of innovative pharmaceutical products. The company has pioneered the use of stable isotopes and NMR in gastroenterology, metabolic diseases and oncology.

INFAI's laboratories in Cologne, Germany are equipped with the most advanced NMR and NMR imaging instrumentation. These facilities are used for in house research and product development and are also available for collaborative and contract research. In the last years we have developed a range of non-invasive and highly effective stable isotope breath tests. One

of these tests is already licensed and available for the routine diagnosis of Helicobacter pylori infection. Other tests to determine gastric emptying rate and pancreatic insufficiency will soon be available.

INFAI Institut für biomedizinische Analytik und NMR Imaging GmbH

NMR spectroscopy and NMR imaging are used at INFAI to investigate a range of metabolic disorders and malignant conditions. The non-invasive characteristics of these techniques make them particularly suitable for pediatric use.

INFAI is affiliated with a range of companies throughout Europe.

- Target DiscoveryTarget ValidationHit Identification
- Lead Optimisation
- Preclinical Studies
- Clinical Trials

Insilico Biotechnology AG

Meitnerstraße 9 Founded: 2001 70563 Stuttgart Employees: n.a.

T +49 (711) 460594-19 info@insilico-biotechnology.com F +49 (711) 460594-10 www.insilico-biotechnology.com



- O Target Discovery
- O Target Validation
- Hit Identification
- Lead Optimisation
- Preclinical Studies
- O Clinical Trials

Insilico Biotechnology AG develops and delivers predictive Digital Twins to advance biopharmaceutical process development and manufacturing.

Insilico Digital Twins of cell culture processes lead to superior productivity, product quality, and process robustness.

Groundbreaking predictive power is achieved by exploiting process data using artificial intelligence and biochemical networks.

As a result, Insilico's unique approach substantially reduces experimental effort, costs of goods, and time to market. Leading biophar-

maceutical companies worldwide use Insilico Digital Twins for cell line development, media design and process control on their journey to Biopharma 4.0 and the factory of the future.

Founded in 2001, Insilico Biotechnology is a privately held company based in Stuttgart, Germany.

Institut für Atemwegsforschung (INSAF) GmbH

Biebricher Allee 34 Founded: 2003 65187 Wiesbaden Employees: 8

T +49 (611) 9854410 sekretariat@insaf-wi.de F +49 (611) 9854348 www.insaf-wi.de



- Target Discovery
- Target Validation
- Hit IdentificationLead Optimisation
- C Lead Optimisation
- Preclinical Studies
- Clinical Trials

insaf is dedicated to research and development of novel therapies and applications in respiratory medicine, with particular focus on asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis.

We support clients from early stages of drug target identification through to design and performance of clinical studies phases I to IV.

In the past 15 years, we have conducted more than 100 clinical trials in respiratory indications in different severity stages. Insaf management is represented by renowned international experts and KOLs in the field of asthma and COPD management who frequently engage in educational activities, lectures, advisory boards and trial monitoring committees.

IQVIA RDS GmbH



Unterschweinstiege 2–14 60549 Frankfurt T +49 (69) 6604-0 Founded: 1954 Employees: 500

info.germany@iqvia.com

www.iqvia.com

IQVIA is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry.

Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science – leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science – to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes.

Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersec-

tion of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 61,000 employees, IQVIA conducts operations in more than 100 countries.

In Germany the IQVIA organization has about 1.800 employees of which 500 are focused on delivering best in class contract research services including full functional service provisions.

Together with our consulting, analytics and contract sales and medical solutions teams we are providing also a full service to companies who are planning to enter the Germany market.

- Target Discovery
- O Target Validation
- O Hit Identification
- Lead OptimisationPreclinical Studies
- Clinical Trials

JPT Peptide Technologies GmbH





JPT Peptide Technologies is an ISO 9001:2015 certified and GCLP compliant innovative service provider and research & development partner.

JPT's proprietary peptide technologies help to advance projects for a variety of applications such as

- · Development of vaccines and immunotherapies
- Immune monitoring and diagnostic content research
- \cdot Seromarker discovery and validation
- Vaccine target and epitope discovery peptide lead discovery and systematic peptide optimization
- · Discovery, clinical and functional proteomics

JPT is the preferred partner for peptide related projects because of its:

- Proprietary technologies for peptide synthesis and high throughput screening
- Integrated in-house R&D team for organic and medicinal chemistry, immunology and assay development, structural biology, bioinformatics and data management
- · Solid track record of successful R&D projects
- Flexible business arrangements for collaborative projects
- ISO 9001:2015 and GCLP regulated quality assurance system
- Professional project management and communication

JPT offers its services and contract research and development project participation in flexible business arrangements.

- Target Discovery
- Target Validation
- O Hit Identification
- Lead Optimisation
- Preclinical Studies
- Clinical Trials

KOEHLER eClinical GmbH



Hornusstraße 16 Founded: 1987 79108 Freiburg Employees: 50

T +49 (761) 50318-0 info@koehler-eclinical.com F +49 (761) 50318-30 www.koehler-eclinical.com

O Target Discovery

O Target Validation

Hit Identification

Lead Optimisation

O Preclinical Studies

Clinical Trials

Since more than 25 years on the pharma market, KOEHLER eClinical GmbH is a mid-size specialty CRO with more than 25 years experience in providing value-added services for our customers. With its strong heritage, KOEHLER eClinical is a major player in biostatistics, covering all aspects of the discipline including all study phases as well as biostatistical and regulatory consulting, meta-analyses, data integrations and -standardizations.

As specialist for data-centric approaches for decades now, the company operates its proprietary software VITESSA as a combined tool for EDC and clinical trial management. Tailor-made and customized eClinical solutions are a part of our service promise.

We provide full service support for local and global trials with centralized project management and technology-enabled approaches for early as well as late-phase projects, including NIS, observational and PASS.

LEUKOCARE AG



 Am Klopferspitz 19
 Founded: 2003

 82152 Martinsried
 Employees: 42

 T +49 (89) 780166-50
 info@leukocare.com

 F +49 (89) 780166-511
 www.leukocare.com

O Target Discovery

Target Validation

Hit IdentificationLead Optimisation

Ceau Optimisation

Preclinical Studies

Clinical Trials

LEUKOCARE AG, located in Martinsried, Germany, is a highly specialized biotech company in the field of formulation development. LEUKO-CARE's expertise is based on two elements: the proprietary Stabilizing and Protecting Solutions (SPS®) formulation technology platform and the rational development approach.

LEUKOCARE's proprietary SPS® formulation technology platform is based on a library of up to 100 different, regulatory well-known excipients, e.g. selected amino acids. The excipients used are listed in pharmacopoeias (USP, EP, JP) and many of them are also listed as inactive ingredient by FDA. SPS® formulations are easily adaptable to specific target molecules and

needs and can be used for dry and liquid formulations. The rational development approach combines statistical software and algorithms. It consists of 5 steps: TPP alignment, analytics, basic characterization, formulation development and a stability study.

By combining these two elements, customized and stable formulations will be tailored to the customers' needs. LEUKOCARE's unique approach can be applied to the following range of applications: biologics & biosimilars, virus & viral vectors and biofunctionalized devices.

Life & Brain GmbH



Venusberg Campus 1 Geb. 76 53127 Bonn

T +49 (228) 6885-100 F +49 (228) 6885-101

Founded: 2002 Employees: 40

info@lifeandbrain.com www.lifeandbrain.com

LIFE & BRAIN is a biomedical enterprise and commercial hub of the University of Bonn Medical Centre. The combination of technological know-how and scientific excellence makes LIFE & BRAIN the perfect partner for academic and commercial research.

To date, LIFE & BRAIN GmbH has set up the following business divisions:

LIFE & BRAIN Genomics is one of the leading European service providers for array-based omics analyses. Our services encompass biobanking, nucleic acid extraction, genotyping, epigenetic analysis, expression analysis, third generation long read sequencing and bioinformatics.

LIFE & BRAIN Cellomics specializes in providing stem cell-based neuronal, neuroglial and microglial cell types for disease modelling and target validation. As a leading partner of the stemcellfactory consortium L&B offers consulting services in the field of automated stem cellbased production processes.

LIFE & BRAIN Neurocognition supports preclinical R&D programs in the area of neurodegeneration, neurocognition and functional connectomics by providing electrophysiological characterization of small molecules with focus on target engagement, efficacy and potency in acute rodent and human brain slices, cultures, neurons and animal models.

- O Target Discovery
- Target Validation
- Hit Identification
- O Lead Optimisation Preclinical Studies
- O Clinical Trials

Lionex GmbH

Salzdahlumer Straße 196 38126 Braunschweig Employees: n.a. T +49 (531) 2601-266 info@lionex.de F +49 (531) 2601-159 www.lionex.de



LIONEX is a German biotech company active in the fields of biomedicine and human health with special emphasis on TUBERCULOSIS (TB). Our focus is on research and In-Vitro-Diagnostic (IVD) product development for infectious diseases and cancer. LIONEX has recently launched a new IGRA (Interferon Gamma Release Assay) diagnostic test called LIOFeron®TB/LTBI for LTBI (Latent Tuberculosis Infection). It may also react positive in TB patients also but, as for other similar IGRA tests on the market, it cannot differentiate between LTBI and active TB.

LIONEX is a leading manufacturer of highly purified, endotoxin free, mycobacterial antigens for research on tuberculosis and other mycobacterial diseases.¶LIONEX is the licensed, exclusive manufacturer and distributor of a widely known family of endotoxin removal resin under the brand name EndoTrap®. EndoGrade®Ovalbumin is another useful product for research on vaccine development. Bovine tuberculosis tests are also available for research..LIONEX has state of the manufacturing facilities for IVD-Lateral Flow Tests. All products are manufactured in Germany. All productions are done under ISO13485 certified conditions.

We are a highly reliable partner for OEM products for companies active in manufacturing and distribution of such products.

- Target Discovery
- Target Validation
- Hit Identification Lead Optimisation
- Preclinical Studies
- O Clinical Trials

Lipotype GmbH

 Tatzberg 47
 Founded: 2012

 01307 Dresden
 Employees: 16

 T +49 (351) 796-5345
 info@lipotype.com

 F +49 (351) 796-5349
 www.lipotype.com



≅mediagnosť

- Target Discovery
- Target Validation
- O Hit Identification
- O Lead Optimisation
- Preclinical Studies
- Clinical Trials

Lipotype is a leading lipidomics provider and delivers comprehensive, absolutely quantitative lipid analysis services for clinical and biological samples on a high-throughput scale. Drawing on many years of cutting-edge research experience, Lipotype offers high quality targeted global lipidomics services for a wide range of customers and applications.

These services include biomarker identification and mode-of-action studies for clinical researchers, GMP compliant quality control and assay development for pharma and biotech companies, target validation and topical drug development for the cosmetics/dermatology industry,

as well as for the small-scale profiling needs of academic researchers.

Lipotype is a spin-off company from the Kai Simons and Andrej Shevchenko labs of the world-renowned Max-Planck-Institute of Molecular Cell Biology and Genetics in Dresden, Germany.

LIPOTYPE - LIPIDOMICS FOR A BETTER LIFE

Mediagnost GmbH

Aspenhaustraße 25 72770 Reutlingen T +49 (7121) 51484-0 F +49 (7121) 51484-10 Founded: 1985 Employees: n.a.

contact@mediagnost.de www.mediagnost.de



- Target Validation
- O Hit Identification
- Lead Optimisation
- Preclinical Studies
- O Clinical Trials

The Mediagnost Company, founded in 1985, is a research based company dedicated to the development and manufacture of in-vitro diagnostic test systems and cell culture derived biological reagents (viral antigens and antibodies).

Mediagnost has established state-of-the-art labs, certified by the German authorities and in conformity with the laws relating to medical devices, pathogens and genetic engineering. The laboratories in two security levels (L1/S1+L2/S2) are approved for handling human pathogens. The manufacturing processes, adhering to the GLP and GMP standards, are managed by scientists with qualified expertise in immunology, endocrinology, infectiology and virology.

Mediagnost is certified according to ISO 13485:2016. All test systems for clinical diagnostics are in compliance with the European Medical Device Directive 98/79/EC and are CElabeled.

The entire company expertise in developing, validating and manufacturing clinical diagnostic tests, as well as performing them, is available as service!

Mediconomics GmbH



Misburger Straße 81B Founded: 1999
30625 Hannover Employees: 20
T + 49 (511) 560998-0 info@medican

T +49 (511) 560998-0 info@mediconomics.com F +49 (511) 560998-20 www.mediconomics.com

Since 1999 Mediconomics GmbH has been a premier provider for the Pharmaceutical and Biotechnology industries. Our services include but are not limited to: Clinical Trial Services, Data Management, Pharmacovigilance, Product Development, Regulatory Affairs and Medical Writing for both medicinal products and medical devices.

Mediconomics uniquely balances science and business to provide our clients competent and reliable safety and efficacy data on their products and insights into the economic impact a new product might have on the client's overall financial performance.

Mediconomics has earned an excellent reputation with leading enterprise pharmaceutical companies in the EU and the USA for the quality of its work and for its combination of technological innovation and bottom-line orientation.

Successful completion of tasks to client's satisfaction has brought more repeat business and increased new business.

- O Target Discovery
- O Target Validation
- O Hit Identification
- Lead OptimisationPreclinical Studies
- Clinical Trials

MEDICRO GmbH



 Klostersteig 19
 Founded: 2001

 91580 Petersaurach
 Employees: 4

 T +49 (9872) 9699-027
 office@medicro.eu

 F +49 (9872) 9699-029
 www.medicro.de

MEDICRO is a full service CRO with experience of more than 15 years. We offer services for Interventional Studies Phase I–IV, Non-interventional Studies and Medical Device Studies. MEDICRO provide support for: Quality Assurance, Clinical Monitoring, Project Management, Regulatory Affairs, Medical Writing, Clinical Trial Management

At MEDICRO, a nationally and internationally operating contract research organisation, we focus our efforts on supporting your trial, your project, your wishes. We conduct clinical trials in the field of pharmaceuticals and medical technology with utmost precision, in compliance with GCP, without red tape and with the highest quality standards. The costs for developing

medicinal products and medical devices are growing continuously.

MEDICRO is fully committed to supporting you throughout the duration of your project, so that delays can be recognised early on and prevented. Our staff members' motivation will make your trial a success.

Special Services: Certified Translation Service (English, Spanish, French, German).

MEDICRO organise Seminars AMG-Grund-, Aufbau- und Aufrischungskurs. Also Seminars for Medical Devices (MPG – MDR). We have a course for study nurses and a CRA beginner course.

- Target Discovery
- Target Validation
- Hit IdentificationLead Optimisation
- Preclinical Studies
- Clinical Trials

menal GmbH

Im Hausgrün 15 Founded: 1992 79312 Emmendingen Employees: 20 T +49 (7641) 9333-46 info@menal.de F +49 (7641) 9333-489 www.menal.de



- O Target Discovery
- O Target Validation
- Hit Identification
- O Lead Optimisation
- Preclinical Studies
- Clinical Trials

menal GmbH is a GLP/GCP/GMP bionanalytical laboratory based in Emmendingen/Germany. Since 1992 menal supports the pharmaceutical industry holistically in their research and development. Pharmakokinetic and Pharmacodynamic/Biomarker analytics are our strength.

menal's bioanalytical performances for R&D, preclinical and clinical studies: ¶Coagulation Assays, HPLC-UV, LC/MS/MS, ELISA, Enzym Activity Assays.

Since 2016 menal is able to provide high quality GMP analytics. Frequently in demand are potency assays like Anti IIa/Anti Xa HEPARIN and enzyme activity assays.

Customized projects and assays can be realized based on the high flexibility and more than 25 years of experience.

Merck Chemicals GmbH - Teil der Merck KGaA



Feldbergstraße 80 Founded: 1668 64293 Darmstadt Employees: 10,000

T +49 (6151) 3599-499 GEcustomerservice@merckgroup.com

F +49 (1805) 045-644 www.sigmaaldrich.com

Target Discovery

Target Validation Hit Identification

Lead Optimisation

O Preclinical Studies

Clinical Trials

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, Millipore-Sigma and EMD Performance Materials.

Before researchers can make scientific breakthroughs, they must have access to state-ofthe-art tools, services and expertise in order to perform experiments and engineer new products. From drug discovery and development to manufacturing and diagnostics, Merck are dedicated to solving the toughest problems in life science by collaborating with the global scientific community. Our 300,000 products range from lab water systems to gene editing tools, antibodies, cell lines and end-to-end systems to manufacture drugs. We work closely with our customers from academia, biotech and pharma to help deliver the promise of their work better, faster and safer.

To find out more about our products, please visit www.SigmaAldrich.com

metabion GmbH - metabion international AG



Semmelweisstraße 3 82152 Planegg T +49 (89) 899 363-0 F +49 (89) 899 363-11 Founded: 1997/2004 Employees: n.a. regina@metabion.com www.mymetabion.com

metabion is a globally leading supplier of custom nucleic acids renowned for its focus on reliable supplies of consistently high quality products and services.

Starting its operations in late 1997, metabion has been providing the areas of academic research, pharmaceutical & biotechnology development, and genetic diagnostics (human, animal, food, environmental) with a wide range of synthetic DNA/ RNA-based compounds for more than 20 years. Successfully translating highest quality standards into daily practice is the core of metabion's business philosophy and key to its popularity at the same time. Careful evaluation and implementation of new and promising technologies

and products are complementing metabion's progressive and innovative approach within a healthy and sound business setup.

metabion's highly professional team of molecular biologists, chemists, engineers and process technicians is dedicated to understand, anticipate, meet, and ideally exceed market requirements and quality standards by diligently listening to our customers' needs.

Daily applying and improving our core expertise in custom synthesis of nucleic acids and derivates thereof, which are key components for any molecular biological R&D activities, we strive to contribute our share to Life Sciences' progress.

- Target Discovery
- Target Validation
- Hit Identification
- Lead Optimisation Preclinical Studies
- O Clinical Trials

Metronomia Clinical Research GmbH



Paul-Gerhardt-Allee 42 81245 München T +49 (89) 829265-100

Employees: 65 info@metronomia.net F +49 (89) 829265-099 www.metronomia.net

Founded: 1980

Metronomia Clinical research: Data. People. Excellence.

Metronomia is an expert CRO for biostatistical consulting, biostatistical services and clinical data management, located in Munich, Germany.

We offer high-quality clinical research services to pharmaceutical and biotech companies, along with the medical device industry.

Since the foundation in 1990, Metronomia was successfully involved in more than 500 clinical projects, covering every clinical stage and project size throughout all major therapeutic areas.

Our services: · Biostatistical consulting · Biostatistical services and statistical programming · Clinical data management · Medical Writing · Randomization/IWRS

Experience: · More than 500 projects · All clinical phases and NIS · All major therapeutic areas · Small molecules, biologicals, biosimilars, medical devices, orphan drugs and pediatric clinical trials

Our commitment: · Exceptional flexibility · Personal service through stable project teams · Productive, long-lasting, trustful relationships · High-quality and reliability of our data · Efficient processes and state-of-the-art technology

- O Target Discovery
- Target Validation
- Hit Identification Lead Optimisation
- O Preclinical Studies
- Clinical Trials

micro-biolytics GmbH



Schelztorstraße 54–56 Founded: 2001 73728 Esslingen a.N. Employees: 24

T +49 (711) 400 52-410 info@micro-biolytics.com F +49 (711) 400 52-800 www.micro-biolytics.com

- Target Discovery
- Target Validation
- O Hit Identification
- Lead Optimisation
- O Preclinical Studies
- O Clinical Trials

MICRO-BIOLYTICS is a leading service and solution provider for analytical chemistry with industry expertise across Pharmaceutical, Chemical, Life Science and Food industry.

The company delivers comprehensive services that support its customers digitalization roadmap towards efficient, secure and reliable value chains.

Our AquaSpec™ MIRA Analyzer revolutionizes the supply chain of the chemical, biotechnical and pharmaceutical industries through digital enablement of chemical analysis through cloud, artificial intelligence and big data technologies.

Since 2001, micro-biolytics has been developing and producing analytical instruments for digitizing liquids that can do more – and are better.

We are constantly inventing, testing and optimizing.

Microcoat Biotechnologie GmbH



T +49 (8158) 9981-0 a.graentzdoerffer@microcoat.de

F +49 (8158) 9981-10 www.microcoat.de



- Target Discovery
- Target Validation
- Hit IdentificationLead Optimisation
- C Lead Optimisation
- Preclinical Studies
- Clinical Trials

Microcoat's Laboratory Services comprise a comprehensive selection of both off the shelf and individualized solutions, supporting large molecule drug development from the very early discovery phase through GLP preclinical research, GCP clinical studies and up to postmarketing surveillance.

In close cooperation with our customers, we aim for best performance, based on an extensive portfolio of advanced technologies paired with uncompromised quality standards.

Based on more than 25 years of professional experience, we assist our clients in the development and tailor-made validation of bioanalytical assays for their specific targets and applications.

- PK and immunogenicity assays for pre-clinical and clinical environments in compliance with all relevant guidelines.
- Biomarker selection support, assay validation and sample analysis based on a broad technological spectrum ranging from high-throughput automation to ultra-sensitive multiplexing platforms.
- Fully validated bioanalytical LIMS for management of studies and samples, guaranteeing traceability and data integrity at highest standards.
- Dedicated teams with a high degree of academic members supervise our projects from conception to result.

Contact us to discuss your individual request with our bioanalytical experts.

MicroDiscovery GmbH

• MicroDiscoveru

Marienburger Straße 1 Founded: 2000 10405 Berlin Employees: n.a.

T +49 (30) 44350-900 gregor.keeve@microdiscovery.de

F +49 (30) 44350-9010 www.microdiscovery.de

MicroDiscovery develops and produces software and hardware solutions for mHealth, in-vitrodiagnostics and biomedical research enabling personalized medicine.

Our innovative analysis system, mo:Test, a smartphone based user friendly reader for lateral flow test evaluation makes diagnostics mobile. Quick high quality readout, quantification and reliable documentation are guaranteed in all applications. Intelligent integration of a smartphone makes the system fully autonomous and reduces maintenance effort. mo:Test is easily adaptable to single or complex multiparameter assays.

MicroDiscovery has a strong track record in creating analysis systems for molecular data, image analysis, classification and medical device control. This includes the design and realization of dedicated algorithms in the fields of Genomics, Proteomics and Metabolomics.

Solutions can be developed and documented as required for CE certification and FDA compliance. Complementary bioinformatics and biostatistics services support your study planning, biomarker validation, data processing, data integration and data management. MicroDiscovery is DIN ISO 9001:2015 certified by TÜV Rheinland.

- O Target Discovery
- O Target Validation
- Hit Identification
- Lead Optimisation O Preclinical Studies
- O Clinical Trials

MicroMol GmbH

Am Hubengut 3 Founded: 1996 76149 Karlsruhe Employees: 20 T +49 (721) 9415213 info@micromol.com F +49 (721) 9415214 www.micromol.com



MicroMol GmbH Company

MicroMol has focussed its portfolio on 3 defined topics within the field of Biological Risk Assessment.

The section of Biological Safety concentrates on the analysis of Medical Devices (ISO 10993), Pharmaceuticals and Biologics in general. In this context MicroMol offers an independent and accredited platform for: • Pyrogen testing by MAT • Cytotoxicity in vitro · Skin testing in vitro Irritation/Sensitisation/Corrosion · Determination of Hemocompatibility · Determination of Genotoxicity

The section of Bioanalytics focusses on several aspects within the field of Protein-/Immuneand Cell analytics as well as the assessment of

biological contamination, especially: · Protein characterisation by amino acid composition (ninhydrin positive substances according to Ph.Eur. 2.2.56) · Protein characterisation by size and immunological reactivity · Determination of biological contamination (DNAse, RNAse, residual DNA/RNA/Protein, HCP, Mycoplasma)

Last but not least the platform is complemented with a section for Microbiology concentration on the analysis of: · Cell bank purity/Bacteriophage detection and characterisation · Bioburden, LAL, and Genotoxicity testing

Micromol is GMP certified and ISO 17025 accredited.

- O Target Discovery
- Target Validation
- Hit Identification Lead Optimisation
- Preclinical Studies
- Clinical Trials

Micromun – Privates Institut für Mikrobiologische Forschung GmbH

Walther-Rathenau-Straße 49a Founded: 1993 17489 Greifswald Employees: 19

T +49 (3834) 515-600 micromun@micromun.de F +49 (3834) 515-605 www.micromun.de



Target DiscoveryTarget Validation

Hit Identification

Lead Optimisation

O Preclinical Studies

O Clinical Trials

MICROMUN Privates Institut für Mikrobiologische Forschung GmbH is a specialised private laboratory which offers complete services on the field of virology.

MICROMUN develops test methods and investigates drugs according to GMP for pharmaceutical manufacturers.

MICROMUN applies cell biological-, molecular biological-, immuno chemical- and biochemical methods for this purpose.

MICROMUN provides methods to determine the infective virus burden in drugs which are derived from biological sources. Drug preparations are quantitatively inspected for the presence of bacterial endotoxins with the aid of the LAL assay according to the european pharmacopoeia.

MICROMUN gives expert opinion on disinfectants with respect to their action against viruses. MICROMUN sells a spectrum of diagnostic antigens from own production for the creation of immunologicals assays.

MICROMUN investigates substances with respect to antiviral and cyto toxic potency and developes corresponding assays on customer request.

MICROMUN carries out virus- and TSE clearance studies according to the rules of GLP to proof the safety of pharmaceutical manufacturing processes.

MICROMUN's animal laboratory is specialised on toxicological investigations in connection with TSE and is certified according to GLP.

Minerva Analytix GmbH

Ladestraße 6 Founded: 2013 15834 Rangsdorf Employees: 9

T +49 (33708) 5282-0 info@minerva-analytix.com F +49 (33708) 5282-99 www.minerva-analytix.com



Target Discovery

Target ValidationHit Identification

O I -- - I O -- ti---i---ti---

Lead Optimisation

Preclinical Studies

Clinical Trials

Minerva Analytix develops, validates and performs assays for routine or custom detection of microbial contaminations.

Our service portfolio includes mycoplasma, bacteria and virus diagnostic and contamination control.

We perform analysis on various biotechnological materials, such as cell cultures or biopharmaceutical products e.g. ATMPs, media or supplements. Since your time is precious our focus are rapid microbiological methods i.e. nucleic acid amplification (NAT) methods.

Our methods are state-of-the-art using the latest technology available in biopharmaceutical industry.

Team up with us to profit from more than 18 years of experience gained by own research and intensive partnering.

MLM Medical Labs GmbH



 Dohrweg 63
 Founded: 1993

 41066 Mönchengladbach
 Employees: 80

 T +49 (2161) 4642-102
 info@mlm-labs.com

 F +49 (2161) 4642-190
 www.mlm-labs.com

MLM Medical Labs is a GLP-certified, CLIA-, CAP- and ISO15189 accredited central laboratory dedicated exclusively to clinical trials.

MLM offers full laboratory services, including a whole range of analytics: standard safety profiles, such as blood counts, coagulation, urinalysis, clinical chemistry, and analyses of biomarkers, drug compounds, metabolites and molecular diagnostic parameters.


The MLM lab is on duty 365 days a year to ensure valid results with a quick turnaround time. With their strategic partners Cenetron Central Laboratories in Austin, USA and Teddy Clinical Research Laboratory in Shanghai, China MLM

offers central lab services in over 40 countries, especially in Europe, USA and China.

The extensive lab portfolio is complemented by a superior IT infrastructure (e.g. mlm online®, MLM Sample Storage System®) and the MLM Kit Building® services for customized sampling kits.

- O Target Discovery
- O Target Validation
- O Hit Identification
- Lead OptimisationPreclinical Studies
- Clinical Trials

OakLabs GmbH



 Neuendorfstr. 16b
 Founded: 2011

 16761 Hennigsdorf
 Employees: 12

 T +49 (3302) 2265-479
 info@oak-labs.com

 F +49 (3302) 209-2705
 www.oak-labs.com

OakLabs GmbH is a privately held Al company founded in 2011 near Berlin, Germany. It collaborates with pharma and diagnostic companies worldwide to develop predictive biomarkers of superior accuracy and thus to boost the success of drugs in the clinical trials or on the market.

OakLabs can look back at more than 8 successful years on the market with a proven track record and an ISO 9001 certification which was acquired in 2018. In the same year, a new office in Boston, USA, opened.

OakLabs' team of life scientists and quantum physicists has extensive real-world experience turning drug development projects into success stories.

- Target Discovery
- Target Validation
- Hit IdentificationLead Optimisation
- Preclinical Studies
- Clinical Trials

OmicScouts GmbH

Lise-Meitner-Straße 30 85354 Freising T +49 (8161) 976289-0 F +49 (8161) 976289-1 Founded: 2014 Employees: n.a.

info@omicscouts.com www.omicscouts.com omicscouts

OmniComm^a

Target Discovery

Target Validation

Hit Identification

Lead Optimisation

Preclinical Studies

Clinical Trials

OmicScouts is a chemical proteomics company focused on supporting drug and biomarker discovery with its unique expertise and innovative technologies.

Founded by leading proteomics researchers, the company has a track record in delivering significant collaborations with top pharmaceutical and biotechnology companies.

We provide and develop proteome-wide assays that work with native proteins in a physiological setting and enable the identification of small molecule drug targets, target engagement markers, molecular mechanisms of action and drug response biomarkers.

OmicScouts supports your drug and biomarker discovery projects with end-to-end solutions tailored to project specific needs.

OmniComm Europe GmbH

Kaiserstraße 139–141 53113 Bonn

T +49 (228) 227440

Founded: 2007 Employees: 20

infoeurope@omnicomm.com

www.omnicomm.com



- Target Validation
- O Hit Identification
- Lead Optimisation
- Preclinical Studies

Clinical Trials

History and mission

Founded in 1997, OmniComm Systems, Inc. has developed into a leading global provider of clinical data management technology. With approximately 180 employees, OmniComm has offices around the globe. The company's commitment to innovation is evident in its introduction of major product enhancements every year for the last 17 years. Leveraging an extensive global experience from more than 6,000 clinical trials, OmniComm provides comprehensive eClinical solutions for research.

Highlights

- $\boldsymbol{\cdot}$ Data centers in in the U.S., Europe and China.
- EU-U.S. Privacy Shield Framework and Swiss-U.S. Privacy Shield Framework Certification.

- 6,000+ studies worldwide, involving more than 65,000 investigator sites in more than 60 countries. 45,000+ eTrained users.
- Experience in 30+ therapeutic areas, Phase I-IV, Medical Device, Academic, NIH/Government, Nutraceutical.
- User support around the clock with full-service customer support in 18 languages. 100% staffed with OmniComm employees in four locations worldwide (USA, Germany, Japan, India).
- Interoperability with external systems to quickly and easily exchange data. Our current technology supports CDISC, SDTM, ODM, CDASH, HL7 and E2B."

PEPperPRINT GmbH



Rischerstraße 12 Founded: 2001 69123 Heidelberg Employees: 25

T +49 (6221) 726-4488 pepperchip@pepperprint.com

F +49 (6221) 726-4475 www.pepperprint.com

PEPperPRINT is the leading provider of high density peptide microarrays for linear and conformational epitope mapping, antibody validation, antigen and epitope discovery and serum bio-

marker development in cancer, autoimmune and infectious diseases for the development of IVD and CDx tests.

The company, located in Heidelberg, provides the PEPperCHIP® Peptide Microarray platform with an unrivalled content flexibility, signal quality and peptide diversity. Besides a number of standard peptide arrays, user defined custom peptide microarrays can be prepared in short turnaround times based on a proprietary laser

printing technology. PEPperCHIP® Peptide Microarray can be analysed by the customer or by PEPperPRINT experts. The PEPperMAP® Service portfolio comprises all microarray-based experiments, data analysis and a comprehensive report.

We are looking for academic and industrial researchers interested in new biomarkers for detection or monitoring of autoimmune and infectious diseases, pharma companies for patient stratification in immuno-oncology and diagnostic companies for licensing our rheumatoid arthritis, psoriatic arthritis and Zika virus epitope biomarkers.

- Target Discovery
- Target Validation
- Hit Identification
- Lead Optimisation
- Preclinical Studies
- Clinical Trials

peptides&elephants GmbH



 Neuendorfstraße 20b
 Founded: 2001

 16761 Hennigsdorf
 Employees: 12

 T +49 (3302) 202-2000
 lips@peptides.de

 F +49 (3302) 202-2001
 www.peptides.de

peptides&elephants, based on its innovative and integrated technologies, is providing the full range of peptides for all research areas.

Our catalogue of immunological peptides has grown over 18 years of innovative and high-quality peptide synthesis expertise. We are able to provide you with high-quality peptides for various applications as neurosciences, cell signaling and cell penetrating, cardiovascular, diabetes, cancer and apoptosis, host defense, epigenetics, peptides hormones.

Through product innovation, responsive service and ongoing support we help our customer to take their studies to success.

peptides&elephants, your research is our priority!

- Target Discovery
- Target Validation
- Hit Identification
- Lead OptimisationPreclinical Studies
- O Clinical Trials

PharmaInformatic

PHARMA INFORMATIC

Friesenstraße 36 26721 Emden T +49 (4921) 993360

F +49 (4921) 993361

Employees: n.a. mail@pharmainformatic.com www.pharmainformatic.com

Founded: 2004

Target Discovery

O Target Validation

Hit Identification

Lead Optimisation

Preclinical Studies

Clinical Trials

Pharmalnformatic provides cheminformatic services and predictive tools to optimize drug discovery. Since 2004 we develop comprehensive ADME/Tox databases. They contain pharmacokinetic results from human clinical trials and preclinical animal trials.

Reliable tools to predict ADME/Tox-properties of compounds such as oral bioavailability, clearance, elimination half life, volume of distribution, plasma protein binding or toxicity can be derived from our databases in order to identify and prioritize promising drug candidates.

The expert system IMPACT-F forecasts druguptake of a compound in humans. It is used by pharmaceutical companies in different therapeutic areas such as diabetes, inflammation, antivirals, autoimmune diseases and cancer for selection and prioritization of drug candidates, to optimize leads and to evaluate oral bioavailability before clinical trials in humans.

This ranking allows the most efficient drug-candidates to be chosen for further development."

PHARMALOG Institut für klinische Forschung GmbH



Oskar-Messter-Straße 29 85737 Ismaning T +49 (89) 544637-0 F +49 (89) 544637-50 Founded: 1983 Employees: 30

pharmalog@pharmalog.com www.pharmalog.com

Target Discovery

Target ValidationHit Identification

O I -- d O-ti--i--ti--

Lead Optimisation

Preclinical Studies

Clinical Trials

PHARMALOG your professional partner for clinical studies. Our team of academics undertakes phase I and phase II–IV studies for you.

We work for the pharmaceutical and biotechnology industries and for producers of food supplements, cosmetics and medical devices.

We are also happy to implement post-marketing and pharmacoeconomic studies for you. We undertake both complete research projects and special tailored services depending on your specific requirements.

We have experience in the performance of multinational and national studies with a network of centres throughout Europe.

We offer excellent value for your money having short channels of communication and direct assignment of responsibility for efficient operations.

PortaCellTec biosciences GmbH

 Philipp-Reis-Str. 2A
 Founded: 2009

 37075 Göttingen
 Employees: n.a.

 T +49 (551) 30966440
 info@portacelltec.de

 F +49 (551) 30966442
 www.portacelltec.de



PortaCellTec (PCT) provides a broad spectrum of assays with hepatic/renal uptake transporters (e.g. OATs, OCTs, OATPs) as well as efflux transporters (e.g. MDR1, BCRP and BESP) to investigate the inhibitory potential and substrate characteristics of drugs. As recommended by FDA and EMA PCT perform in vitro studies with validated drug transporters stably-transfected in HEK-293 cells.

As experts on drug transporter studies, we provide the following services:

- · Consulting service for transporter selection
- Advice regarding FDA and EMA guidelines for SLC- and ABC-Transporter proteins

- · Customized experimental design
- · Detailed study plan
- · Professional performance of transporter assays

Inhibition studies

- · Two point inhibition
- · Determination of IC50 value
- Determination of the inhibition character by Dixon Plot analysis

Substrate studies

- Transport kinetics: time- and concentration dependent uptake
- · Determination of affinity (Km and Vmax)
- · Study report adapted to customers' needs.

- Target Discovery
- Target Validation
- Hit IdentificationLead Optimisation
- Preclinical Studies
- O Clinical Trials

preclinics Gesellschaft für präklinische Forschung mbH



 Wetzlarer Straße 20
 Founded: 2006

 14482 Potsdam
 Employees: 15

 T +49 (331) 243433-50
 info@preclinics.com

 F +49 (331) 243433-51
 www.preclinics.com

preclinics is a CRO that offers preclinical studies for the development of drugs, drug delivery formulations and medical devices.

We are experienced in cardiovascular, inflammatory, orthopedic, hematological and oncological indications. Especially the development of new models for efficacy testing of novel compounds and therapeutical concepts is a focus of our services.

One major product is the Revolyzer, a revolution analyzer for voluntary running assays (VRA). VRA are a versatile and promising method that became very sensitive and convenient with the Revolyzer.

Besides in vitro culture assays, xenograft models are available for in vivo testing of e.g. biologics or biosimilars on human targets. preclinics also offers the custom immunization of various species – from mice to horses.

Most interesting is the immunization of Ilamas and alpacas for generating heavy-chain antibodies and VHHs.

From all species we also provide high quality fresh blood or tissue products.

- Target Discovery
- Target ValidationHit Identification
- Lead Optimisation
- Preclinical Studies
- O Clinical Trials

Premier Research

premier research

Europaplatz 5 Founded: 1989 64293 Darmstadt Employees: 56

T +49 (6151) 520-1600 Administration-Darmstadt@premier-research.com

F +49 (6151) 520-1602 www.premier-research.com

- O Target Discovery
- O Target Validation
- Hit Identification
- O Lead Optimisation
- O Preclinical Studies
- Clinical Trials

Premier Research, a clinical research company, is dedicated to helping biotech, specialty pharma, and device innovators transform life-changing ideas and breakthrough science into new medical treatments.

As a global company, Premier Research specializes in the use of innovative technologies for smart study design and trial management to deliver clean, conclusive data to sponsors.

Whether it's developing product lifecycle strategies, reducing clinical development cycle times, securing access to patients, navigating global regulations, maximizing the impact of limited rare disease data, or providing expertise in

specific therapeutic areas, Premier Research is committed to helping its customers answer the unmet needs of patients across a broad range of medical conditions.

Visit premier-research.com.

PRIMACYT Cell Culture Technology GmbH



Hagenower Straße 73 Founded: 2004
19061 Schwerin Employees: n.a.
T +49 (385) 3993-600 info@primacyt.de

F +49 (385) 3993-602 www.primacyt.com and www.primacyt.services

- Target Discovery
- Target Validation
- O Hit Identification
- Lead Optimisation
- Preclinical Studies
- O Clinical Trials

PRIMACYT is a leading provider of in vitro technologies and services for product development in human and animal health and for bioaccumulation and clearance studies in the area of environmental toxicology.

PRIMACYT has a laboratory certified according to Good Laboratory Practice (GLP) since 2006 and serves as a reference laboratory for the European Union since 2013.

The knowledge of drug affinity and drug-drug interaction (DDI) to uptake and efflux transporters is a fundamental requirement in drug development, recommended by the Pharmaceuticals Medical Devices Agency (PMDA), the Food and

Drug Administration (FDA), and the European Medicines Agency (EMA).

Primacyt has established and validated an assay platform utilising stable transfected HEK-293 cell lines and primary human and animal hepatocytes to assay drug transporter activities.

In addition, we offer studies to analyse hepatotoxicity, metabolism, and Cytochrome P450 activities in 2D and 3D hepatocyte cultures.

proDERM GmbH




Kiebitzweg 2 22869 Schenefeld T +49 (40) 839 358-0 F +49 (40) 839 358-39 Founded: 1994 Employees: 100 info@proDERM.de www.proDERM.de

proDERM is an internationally renowned CRO with a specialized focus on studies relating to skin and mucous membranes. The institute offers customized and innovative solutions to Sponsors worldwide. The services include phase I studies in a dedicated clinic as well as multicenter studies in their growing network of qualified sites in Germany.

proDERM has established an excellent reputation as a high-quality provider of trial services, on the basis of an outstanding technical set-up and expertise, including Confocal Microscopy, Raman Spectroscopy and many state-of-the art skin measuring devices.

- Target Discovery
- O Target Validation
- O Hit Identification
- Lead OptimisationPreclinical Studies
- Clinical Trials

Profil Germany GmbH



Founded: 1999 Employees: 450 contact@profil.com www.profil.com



As a full service CRO, Profil carries out early phase clinical trials for research on obesity, (pre) diabetes, and diabetes complications. Profil was founded in 1999 as a spin-off of an academic study group at the department of metabolic diseases and nutrition at University of Düsseldorf.

One of the core technologies is the hyperinsulinemic euglycemic clamp, used to address action profiles of insulin and insulin analogues, beta cell function and insulin sensitivity.

Profil has been involved in the development of all major antidiabetic compounds and enjoys an excellent scientific reputation worldwide. By owning a database of more than 25.000 well characterized individuals (healthy, healthy at-risk, type 1 and type 2 diabetes) Profil can recruit even the most complex studies in this area.

Profil has a fully GMP certified pharmacy and two in-house clinics with 80+ beds and holds expertise in Data Management & Statistics and Regulatory Affairs.

- Target Discovery
- O Target Validation
- Hit IdentificationLead Optimisation
- O Preclinical Studies
- Clinical Trials

ProJect Pharmaceutics GmbH

d: 2010

Fraunhoferstraße 22 Founded: 2010 82152 Martinsried Employees: 10

T +49 (89) 452289-700 info@project-pharmaceutics.com F +49 (89) 452289-717 www.project-pharmaceutics.com

- O Target Discovery
- O Target Validation
- Hit Identification
- Lead Optimisation
- Preclinical Studies
- Clinical Trials

Development. Formulation. Process. Packaging.

ProJect Pharmaceutics is one of the leading European CROs specialised in accelerated, state-of-the-art formulation and drug product development for (bio-)pharmaceuticals, biologics, ADCs, small molecules and cytotoxics (up to OEL4), as also viral and non-viral nanoparticular products (up to BSL-2).

Services and solutions

· Biopharmaceutics · Formulation profiling, preformulation, early state and late phase formulation, liquid and lyophilized · Highly concentrated protein formulation · UF/DF concentration studies · Downstream process optimisation · Forced stress and stability studies · Freeze-drying from organic solvent systems up to liposomal encapsulation · Lyophilisation in vial, dual chamber system, syringe, bulk tray, containers in nest&tub configuration · In-depth analytical evaluation · Selection of suitable container closure system · Evaluation of process robustness and design space · Smooth technology transfer and scale-up

We support our worldwide clients to develop a consistently high-quality pharmaceutical product, scalable and manufacturable under GMP conditions. Being teamed up with manufacturing experts (CMO) allows one-stop-shop solutions.

· Aseptic manufacturing of preclinical supplies.

www.project-pharmaceutics.com

Prolytic GmbH

 Weismüllerstraße 45
 Founded: 2003

 60314 Frankfurt am Main
 Employees: 16

 T +49 (69) 3487 234-10
 info@prolytic.de

 F +49 (69) 3487 234-99
 www.prolytic.de



- Target Discovery
- Target Validation
- O Hit Identification
- Lead Optimisation
- Preclinical Studies
- Clinical Trials

Prolytic is a German GLP/GCP laboratory for bioanalysis and pharmacokinetic evaluation. We provide our clients with the development and validation of analytical methods, analyse samples from pre-clinical, clinical and toxstudies, and also conduct compartmental and noncompartmental pharmacokinetic evaluation.

Our expertise are:

- Bioanalysis for small and large molecules (LC/ MS-MS and ELISA)
- Pharmacokinetic evaluation with WinNonLin¶-RNA/DNA Analysis
- · Highest Quality through GLP/GCP certification
- · Over 25 years experience in drug development

We are your partner for:

- · Preclinical studies
- · Dose-finding studies
- · Toxicological studies
- · Pharmacokinetic studies
- · Toxicokinetic studies
- · Clinical trials (Phases 0-III)
- · Bioequivalence/bioavailability studies

Proteome Factory AG

Proteome 📙 **Factory AG**

Founded: 2000 Magnusstraße 11 12489 Berlin Employees: n.a.

T +49 (30) 206162-65 service@proteomefactory.com F +49 (30) 206162-67 www.proteome-factory.com

Proteome Factory AG is a Berlin based biotech company specialized in protein analysis with mass spectrometry, chromatography, electrophoresis (1D/2D) and Edman sequencing.

We perform for example sequence validation, profiling of oxidized and acidic variants, determination of glycoforms, confirmation of disulfide pattern and intact masses of biopharmaceuticals APIs like mAB, fusion proteins and others.

For technical enzymes or monoclonal antibodies where hybridoma cells are lost we perform de novo sequence elucidation.

Consult our specialists for a tailored proposal that matches your requirements.

- O Target Discovery
- Target Validation
- Hit Identification
- Lead Optimisation O Preclinical Studies
- O Clinical Trials

PXBioVisioN GmbH

Feodor-Lynen-Straße 5 Founded: 2008 30625 Hannover T +49 (511) 538896-4

Employees: 2 info@pxbiovision.com F +49 (511) 536696-6 www.pxbiovision.com

PXBioVisioN GmbH supports research-based pharmaceutical companies in meeting the many challenges that arise in the discovery, research and development of new active substances and modern drugs.

The methods and techniques summarized under "Peptidomics Technologies" have been researched by us for 20 years, continuously developed and individually adapted according to customer requirements.

PXBioVisioN GmbH accompanies explorative clinical studies and early phases of pharmaceutical research as a service provider and reliable partner on behalf of its customers.

The "Differential Peptide Display" analysis approach: Methodically, the hypothesis-free analysis approach is based on the mass spectrometric analysis of all extracted native peptides and low-molecular weight proteins of biological samples (plasma, tissue, urine, cell culture samples, etc.) intended for differential comparison.

PXBioVisioN

The procedures, processes and protocols are universally and versatilely applicable - as accompanying analytics in clinical study phases and for the clarification of complex pharmacological and clinical effect profiles, for the identification of biomarkers and potential active substances or lead structures for synthetic molecules, for the stratification of volunteers and patients, etc.

- Target Discovery
- Target Validation
- Hit Identification Lead Optimisation
- Preclinical Studies
- O Clinical Trials

SanaClis DE GmbH

Olof-Palme-Straße 15 60439 Frankfurt T +49 (69) 5870035-0

F +49 (69) 5870035-29

Founded: 2000 Employees: 3

 $in fo\hbox{-} germany @ sanaclis.eu$

www.sanaclis.eu



O Target Discovery

Target Validation

Hit Identification

Lead Optimisation

O Preclinical Studies

Clinical Trials

SanaClis was founded in 2000 by seasoned industry experts all of whom have had executive level positions in leading pharma companies and large global CROs. SanaClis is a full-service European CRO offering a comprehensive range of services for clinical trials.

SanaClis has experience of successfully delivering studies for various sized sponsors, starting from virtual biotechs through to top 10 pharma companies. Every project is a priority for the SanaClis team, irrespective size or scope. We believe that every company and professional deserves to feel that they are getting the best possible service, responsiveness, and dedication that we routinely provide to our existing clients.

In addition to being a full-service CRO, SanaClis is one of the very few service providers who has in-house logistics capabilities. This includes QP services, customs brokerage, warehousing and distribution, and sourcing of clinical trial materials, comparators and rescue medication.

SequentiX – Digital DNA Processing





Target Discovery

Target Validation

Hit IdentificationLead Optimisation

Preclinical Studies

• Frecimical Studies

O Clinical Trials

Sequentix – Digital DNA Processing offers bioinformatic services and software for the analysis of DNA, RNA and protein data. ¶¶Our main expertise is the assembly, proof reading and alignment of DNA sequence data, as well as phylogenetic cluster analysis and molecular fingerprint analysis.

For identification of organisms, determination of pathogens and documentation of genetic relatedness we analyse and process our customers raw data sets, combine them with public available sequence data, and deliver publication-ready results and graphics.

We also offer professional digital DNA analyses software for sequence assembly, alignment, cluster analyses and cladistics, and DNA fragment/fingerprint analyses (AFLP, RFLP, t-RFLP, RAPD, PFGE).

Our services help medical and biotechnology companies as well as research institutions save on expensive expertise costs and thereby minimize their own costs.

Seramun Diagnostica GmbH



 Spreenhagener Straße 1
 Founded: 1992

 15754 Heidesee
 Employees: 70

 T +49 (33767) 791-10
 info@seramun.com

 F +49 (33767) 791-99
 www.seramun.com

Seramun Diagnostica GmbH was founded in Brandenburg (near the capital Berlin) more than 20 years ago and has established itself as a competent manufacturer and eveloper of reagents for immunoassays like ELISA, blot and microarrays and for in-vitro diagnostic kits in the field of autoimmune and infectious diseases.

Seramun's services include production, purification and labeling of monoclonal and polyclonal antibodies, production and purification of recombinant proteins and cultivation and preparation of bacterial pathogens at the company's premises.

The product range of reagents comprises chromogenic substrates for HRP and AP for the

application in ELISA, Blot and Microarrays and stabilizers for enzyme conjugates, proteins and proteohormones. Our reagents and services are used worldwide by IVD manufacturers and scientific institutions. An internationally distributed product range of more than 90 CE marked IVDs for the diagnosis of infectious and autoimmune diseases is also based on the company's own reagents and developments.

The new automatable technology platform SeraSpot® offers microarrays on the basis of microtitration plates with up to 25 different parameters in one well for the application in human and veterinary diagnostics.

- Target Discovery
- Target Validation
- Hit Identification
- Lead Optimisation
- Preclinical Studies
- O Clinical Trials

Sirius Fine Chemicals SiChem GmbH



Fahrenheitstraße 1 Founded: 2001 28359 Bremen Employees: 12 T +49 (421) 2208-228 info@sichem.de F +49 (421) 2208-226 www.sichem.de

SiChem synthesizes fine chemicals and diagnostic tools for biochemical, biomedical, and pharmaceutical research (photoactivatable and fluorescent). Recently we supplemented our portfolio by clickable unnatural amino acids and (pegylated) tools for Click-Chemistry. The strained rings which are used in copper-free Click-Chemistry (i.e. transcyclooctene) are also triggering the release of APIs: The click reaction and thus the selected cleavage of tumor-bound antibody drug conjugates (ADCs) can be a powerful tool in ADC therapy.

SiChem's unique expertise is based on the synthesis of compounds with biologically increased bioavailability (prodrugs). The masked drug

candidates are successfully tested against several pathological conditions, for instance cystic fibrosis (CF), diarrhea, and inflammation.

SiChem has developed efficient preparative techniques in the area of enantioseparation and purification (up to the 1,000kg scale). We also support you in the area of classical custom synthesis. If more specialist tasks are involved, such as metabolite synthesis of current APIs (D /13C) we are also the people to turn to.

We provide: multi-step organic synthesis from targets and chiral building blocks – Separation of racemic mixtures – Purifying compounds

- Target Discovery
- Target ValidationHit Identification
- Lead Optimisation
- Preclinical Studies
- Clinical Trials

82110 Germering

T +49 (89) 800650-0

F +49 (89) 800650-555

SSS International Clinical Research GmbH

Landsberger Straße 23/25 Founded: 1993 Employees: 50 info@cro-sss.com www.cro-sss.com



- O Target Discovery
- O Target Validation
- Hit Identification
- O Lead Optimisation
- O Preclinical Studies
- Clinical Trials

SSS International Clinical Research GmbH was founded as a Clinical Research Organisation (CRO) in September 1993 in Munich, Germany.

Since then the company has acquired ample experience in setting-up and running clinical trials in many European countries.

Over the last 20 years SSS has established international co-operations in Western, Central and Eastern Europe. New offices of SSS were opened to cover the Eastern European market with own staff in 2007 (Romania) and 2008 (Poland).

The quality system of SSS was certified according to DIN EN ISO in 1997. In June last 2012 recertification (DIN EN ISO 9001) was performed by Intertek.

Since 2013 SSS International Clinical Research GmbH is member of the German association of contract research organizations (BVMA) after passing a qualification audit.

Services

- · Full service phase II-IV, NIS, IIT
- · International project management
- · Site selection, patient recruitment strategies
- Clinical monitoring
- · GCP training (in-house, on-site, on-line)

StarSEQ GmbH

Johann-Joachim-Becher-Weg 30a 55128 Mainz

T +49 (6131) 3925397

Founded: 2008 Employees: 6 info@starseq.com www.starseq.com



- Target Validation
- Hit Identification
- O Lead Optimisation
- Preclinical Studies
- O Clinical Trials

StarSEQ aims to offer a complete service in the analysis of genetic material. Our main priorities are our orientation towards our customers and our careful advisory service.

Starting in 2008 as a company with an extraordinary affordable DNA sequencing service we have expanded our service covering next generation sequencing, bioinformatics, genotyping, extensive industrial services and personal genomics.

We have important clients throughout 40 countries worldwide, among them giants of the chemical and pharmaceutical industries.

It is our strong belief that our service can add value to your budget.

We promise to you high-quality standards, ensured by our highly motivated scientific team which has more than 30 years experience in DNA sequencing and genome analysis.

SynapCon Ltd.



Wenzel-Jaksch-Straße 2a Founded: 2006 65199 Wiesbaden Employees: 20 T +49 (611) 703-97054 info@synapcon.com F +49 (611) 710-29495 www.synapcon.com

SynapCon Ltd. offers effective innovations and sustainable IT solutions for better performance of your clinical research projects. Our solutions are customized for small and medium enterprises to benefit from almost 30 Years of clinical research and 20 Years of IT architecture experience. EasyClin(c) feasibility, EasyClin(c) TMF, EasyClin(c) ISF and the management modules guarantees remarkable cost and time savings. Our systems are 21 CFR Part 11 compliant and the compliance infrastructure will be delivers. In case you are hosting our systems on your own servers we are glad guiding you thru the validation process.

Due to our experience we can support you using the software in the best way performing your

clinical trial projects better and faster then ever before or your competitors.

EasyClin© is a revolutionary Clinical Trial Management System (CTMS) control and manage the clinical development of pharmaceutics and any kind of medical products.

Our deep knowledge about the entire value chain makes EasyClin® the perfect CTM system, to raise standards and improve the quality of documentation in clinical trials, save time & money along the entire value chain of clinical research.

Please ask for a free online demonstration to learn more about our unique business concept.

- O Target Discovery
- O Target Validation
- Hit Identification
- O Lead Optimisation O Preclinical Studies
- Clinical Trials

SYNLAB Analytics & Services Germany GmbH



Bayerstraße 53, 6. Stock 80335 München T +49 (89) 741393-0

F +49 (89) 741393-39

Founded: 1994 Employees: 300

pharma-munich@synlab.com

www.synlab.de

SYNLAB Pharma, a segment of the Business Unit SYNLAB Analytics & Services Germany GmbH of the SYNLAB Group, offers a very broad range of laboratory services to the biotechnology and pharmaceutical industries as well as to manufacturers of medical devices and novel foods.

SYNLAB Pharma's portfolio includes global clinical trial services, bioanalytical services, advanced biomarker testing, personalized medicine concepts, logistics, long-term sample storage, production monitoring incl. extractables & leachables, product release and stability studies. SYNLAB Pharma supports the complete drug development cycle from preclinical toxicology and PK projects through all clinical phases and beyond.

Our clients take advantage of our large spectrum of analytical methods for drug development and production control; always working in accordance with the highest standards such as DIN/EN ISO/ IEC 17025/15189, GMP, GLP, GCLP or GCP.

See us as your ONE-STOP-SHOP - and take advantage of our experience gained in more than 25 years and 3,500 clinical trials.

- O Target Discovery
- Target Validation
- Hit Identification Lead Optimisation
- Preclinical Studies
- Clinical Trials

Taros Chemicals GmbH & Co. KG

1999 es: 60

 Emil-Figge-Straße 76a
 Founded: 1999

 44227 Dortmund
 Employees: 60

 T +49 (231) 9742-7211
 innovation@taros.de

 F +49 (231) 9742-7219
 www.tarosdiscovery.com

- O Target Discovery
- O Target Validation
- Hit Identification
- Lead Optimisation
- O Preclinical Studies
- O Clinical Trials

Taros, a privately owned chemistry CRO has been serving pharmaceutical, biotech and chemical companies since 1999. Within our drug discovery division, our mission is to accelerate potential new medicines into clinical development. Taros adds considerable value to drug discovery collaborations by boosting collaborators' discovery programs from target validation and hit identification to lead generation and optimization. Taros' capabilities include medicinal chemistry, computational sciences and innovative compound libraries. Taros has been leading the chemistry activities of the European Lead Factory (ELF) and is also in the lead of its recent continuation ESCulab. Moreover Taros is involved in the Drug Discovery Hub Dortmund.

Holistic drug discovery chemistry

Taros core expertise in Drug Discovery encompasses:

· Medicinal chemistry from hit validation to candidate selection · Expertise on many biomolecular targets across all main therapeutic areas · Dedicated group for computational chemistry and molecular modeling · Partners for outsourcing disease biology, HTS, ADME, DMPK, X-ray crystallography · Strong track record in compound library design and production by parallel syntheses · Excellence in custom synthesis, process development and scale-up to pilot plant manufacturing"

TherapySelect Dr. Frank Kischkel



Carl-Bosch-Straße 4 Founded: 2011 69115 Heidelberg Employees: 6

T +49 (6221) 8936-157 kontakt@therapyselect.de F +49 (6221) 8936-158 www.therapyselect.de

- Target Discovery
- Target Validation
- Hit IdentificationLead Optimisation
- C Lead Optimisation
- Preclinical Studies
- Clinical Trials

The intention of TherapySelect is to help individual cancer patients to find an effective anticancer therapy (personalized medicine). TherapySelect's goal is to increase patient's survival and quality of life as well as to reduce costs in healthcare system.

TherapySelect offers the CTR-Test (Cancer Therapy Response-Test), which can measure the efficacy of cancer drugs on living tumor cells to identify the best therapy option for an individual cancer patient before start of a therapy. This test is able to identify inefficient drugs before start of chemotherapy with a very high probability (>95 %). In general the CTR-Test can be used for all drugs directly acting on tumor cells.

Besides using the CTR-Test for cancer patients, the test can also be applied to increase the success of clinical trials. Unsuccessful clinical trials are the most expensive obstacle in drug development. The success of clinical trials can significantly be increased by using a diagnostic test to identify patients susceptible to the specific drug. When a drug is applied to patients, who are resistant to the tested drug, no or wrong conclusions could be drawn regarding the general efficacy of this drug. The CTR-Test can help to find appropriate patients for clinical trials.

TRIGA-S Scientific Solutions



Mühltal 5Founded: 199882392 HabachEmployees: 80T +49 (8847) 69578-0info@triga-s.deF +49 (8847) 69578-29www.triga-s.de

TRIGA-S Scientific Solutions is an owner-managed contract research organization. For more than 20 years we are successfully conducting clinical and technical studies for in-vitro diagnostic products and medical devices. During that time, we successfully completed more than 100 different studies at more than 500 study sites worldwide with more than 1 million samples.

Our study services comprise management, monitoring and logistics. Additionally, we operate a S2 laboratory for contract measurements and controlled storage facilities for human sample material. Furthermore, we provide biostatistics support and cooperate with an excellent network of manufacturers, partner companies

and life-science associations. All our services are based on GxP guidelines and the quality certification DIN EN ISO 9001:2015.

Based on our years of experience, our high quality standard and our excellent team of international scientists, TRIGA-S is a reliable and competent partner for tailor-made solutions in the field of clinical and technical studies.

- Target Discovery
- O Target Validation
- Hit IdentificationLead Optimisation
- Preclinical Studies
- Clinical Trials

vertis Biotechnologie AG

Lise-Meitner-Straße 30 Founded: 2000 85354 Freising Employees: 5 T +49 (8161) 18516-11 info@vertis-bio

T +49 (8161) 18516-11 info@vertis-biotech.com F +49 (8161) 18516-12 www.vertis-biotech.com



VERTIS is a research-oriented company in the field of functional genomics. The strength of our service is customer-oriented flexibility which is based on our innovative technology platform which we have developed in our 20-year history.

Services

We offer innovative tools and strategies for the comprehensive qualitative and quantitative analysis of bacterial and eukaryotic transcriptomes, using state-of-the-art Next Generation Sequencing (NGS) of RNA molecules (RNA-seq).

Special emphasis of VERTIS lies in the analysis of bacterial transcriptomes. We are able to provide specialised applications like dRNA-seq,

tagRNA-seq, dual RNA-seq, Cappable-seq, etc., to our customers. Our consequent use of a robotic system for NGS library preparation guarantees highly reproducible data, more consistent yields and higher quality data.

We offer a complete product line, ranging from project consulting, nucleic acid isolation, NGS library preparation, DNA sequencing to bioinformatic sequence analysis and data mining.

- Target Discovery
- Target Validation
- Hit IdentificationLead Optimisation
- O Preclinical Studies
- O Clinical Trials

Vibalogics GmbH

Vibalogics

Zeppelinstraße 2 27472 Cuxhaven T +49 (4721) 565-400 Founded: 2001 Employees: 50 info@vibalogics.com www.vibalogics.com

- O Target Discovery
- O Target Validation
- Hit Identification
- Lead Optimisation
- Preclinical Studies
- Clinical Trials

Live virus manufacturing, including aseptic fill and finish, is Vibalogics' expertise. We work with virotherapies, including oncolytic viruses and gene vectors and are a partner for companies committed to developing innovative drugs for life-threatening diseases. Our one-stop-shop services include process development, assay development, cGMP-compliant manufacturing, filling, lyophilization, formulation development, and QC testing.

We offer a highly competent team of experts and a biosafety level 2 state-of-the-art facility. Four independent GMP production suites with cleanroom class areas A-D provide a high level of manufacturing flexibility. We deliver highquality clinical trial material including comprehensive GMP documentation to facilitate our customers' product development strategies on time and within budget.

VivaCell Biotechnology GmbH

Ferdinand-Porsche-Straße 5 79211 Denzlingen T +49 (7666) 9028-77 F +49 (7666) 9028-78 Founded: 1999 Employees: 5 info@vivacell.de www.vivacell.de



- Target Discovery
- Target Validation
- Hit IdentificationLead Optimisation
- Preclinical Studies
- O Clinical Trials

Vivacell is a service provider with a strong focus on pharmacological testing (drug efficacy). Our main activities are in the field of phytopharmaceuticals, drugs, nutraceuticals cosmetics and oral care.

Examples of some recent activities:

- Immunmodulation/anti-inflammatory/wound healing/sinusitis/bronchitis (metabolic activity, proliferation, cytokines, leukotrienes, humane monocytes, chondrocytes, keratinozytes)
- Receptor binding studies, neurotransmitterreuptake (anxiety, depression, memory effects, dyspepsia)
- Viral entry model, inhibition viral neuraminidase (common cold)

- Inhibition 5alpha-reductase (hair growth, prostatic hyperplasia)
- Vanilloid (=Capsaicinreceptor) and menthol receptor (pain, warming, cooling, hair growth)
- Histamine-release (allergy), histamine induced inflammation
- · Lipolyse in human primary adipocytes
- · cosmetics screening

Apart of these drug efficacy studies we offer preclinical studies (e.g. Ames Test).

Winicker Norimed GmbH

Deutschherrnstraße 15–19 90429 Nürnberg

T +49 (911) 92680-0 F +49 (911) 92680-8839 Founded: 1993 Employees: 134

wn@winicker-norimed.com www.winicker-norimed.com



Winicker Norimed GmbH, established in 1993, is a full service Contract Research Organization. We offer a full range of services in clinical research from planning through reporting.

In cooperation with hospitals and primary care physicians, we manage phase II–IV clinical trials as well as non-interventional and epidemiological studies with pharmaceuticals and studies with medical devices.

Thanks to our many years of experience in the management and conduct of clinical investigations with medical devices as well as nutritional products with health promoting properties, we are able to provide you with effective and individual solutions.

Another main focus of our work is Market Access and Health Service Research.

- Target Discovery
- O Target Validation
- O Hit Identification
- Lead OptimisationPreclinical Studies
- O Treeminear See
- Clinical Trials

Zentrum für Humangenetik und Laboratoriumsdiagnostik

Lochhamer Straße 29 82152 Martinsried T +49 (89) 895578-0 F +49 (89) 895578-780 Founded: 1998 Employees: 120

info@medizinische-genetik.de www.medical-genetics.de



The diagnostic expertise covers the analysis of body fluids and tissue samples with molecular genetic, cytogenetic, flow cytomteric and biochemical techniques. Our molecular diagnostics portfolio comprises the whole spectrum of advanced technologies such as multi-gene panel sequencing (MGPS), clinical exome sequencing (CES), whole Exome sequencing (WES) and RNA sequencing.


Other applications of next generation sequencing (NGS) include HLA typing, NIPT(Prenatalis® and Veracity®) and Microbiome Analysis (Enteralis™). We also employ several array platforms such as Affymetrix™, Agilent™ or Illumina iScan™ to perform array CGH, SNP array analyses and

methylation profiles. Other important methods include flow cytometry (FACS scan) and tandem mass spectrometry.

The highly qualified medical, scientific and technical staff offers comprehensive and individual support services for physicians regarding all clinical and diagnostic questions.

The interdisciplinary collaboration between five medical specialist areas (Human genetics, Laboratory Medicine, Microbiology/Virology, Transfusion Medicine, Molecular Oncology/Pathology) enables diagnostic questions to be more efficiently, comprehensively and accurately resolved.

- Target Discovery
- Target ValidationHit Identification
- Lead Optimisation
- Lead Optimisation
- O Preclinical Studies
- Clinical Trials





Association of German Biotech Companies (VBU) in DECHEMA e.V.

From its beginning, the VBU (Vereinigung Deutscher Biotechnologieunternehmen) set out to enable technology transfer and facilitate networking between academic research and industry. With a special focus on small and medium sized enterprises, the VBU offers advice and organizes events tailored to give information and support to start-ups during their growth and expansion phase, both nationally and internationally. Being a part of DECHEMA, the large network for chemical process technology and biotechnology, it is the home for people active in research whether in universities, independent research institutions, start-ups or "big businesses". The activities of VBU supplement the approximately 120 topical working groups within DECHEMA, around 20 of them covering biotechnology from Omics and Cell Culture to Bioprocessing and Single-Use Technologies.



www.v-b-u.org | www.dechema.de



German Association of Biotechnology Industries (DIB)

The German Association of Biotechnology Industries (DIB) and its national, European and global networks are the voice and leading industry representation for the innovative and dynamic biotechnology industry that operates in and from Germany. DIB is the biotechnology division of the Association of the German Chemical Industry Association (VCI). DIB's members constitute all in all about 95 % of the biotechnology business operating in and from Germany. DIB's mission is to advocate national, EU and international policies and legislation that uphold a natural science and risk-based approach, foster innovation, operate in a predictable and proportionate way, enable the industry to perform efficiently, protect intellectual property and reward the introduction of new technologies and practices.





Biotechnologie-Industrie-Organisation Deutschland (BIO Deutschland)

The Biotechnologie-Industrie-Organisation Deutschland (BIO Deutschland) is an independent organization for innovative biotechnology companies in Germany. At its offices in Berlin, the association is developing and supporting an innovative industry based on modern life sciences. Founded in October 2004, BIO Deutschland currently has more than 320 member companies and several supporting members and sector partners. To support its members BIO Deutschland engages in a broad range of activities, including lobbying, public relations, and offering business development opportunities. Using a wide range of political initiatives, BIO Deutschland lobbies for improvements to legal parameters for innovative small and medium-sized enterprises. The association is also very active in a broad range of events with the aim of providing biotechnology with a platform for discussion and interaction.



www.biodeutschland.org



Federal Association of Contract Research Organisations (BVMA e.V.)

Founded in July 1991, the »Bundesverband Medizinischer Auftragsinstitute« (BVMA) represents CROs (Contract Research Organisations) in German speaking countries. The association promotes Good Clinical Practice (GCP) and requires from its members a strong commitment to the quality standards adopted at the General Assembly. The BVMA maintains close relations with the pharmaceutical industry, media, physicians/investigators, regulatory authorities and ethic committees, in order to contribute to the continuous development of scientific methodology as well as regulatory and ethical matters in clinical research. BVMA hosts an annual symposium that provides an excellent platform for interdisciplinary exchange between all stakeholders. An informal Get-together the evening before presents a well perceived networking opportunity.



www.bvma.de

HEALTH MADE IN GERMANY

Germany is one of the world's most important providers and exporters of healthcare products and services. The country's innovative medical products set international standards for quality, safety and reliability. German manufacturers and service providers in all health and life sciences segments attract overseas customers and partners and deliver leadership in healthcare innovation.

HEALTH MADE IN GERMANY is the export initiative for the German healthcare industry. It supports international companies and organizations that are interested in establishing contact with potential German partners and suppliers. Set up by the German Federal Ministry for Economic Affairs and Energy (BMWi), the initiative bundles expert market intelligence for easy industry access. One of the initiative's main goals is to promote the German healthcare sector through international networking activities for the mutual benefit of international partners and German companies alike.

HEALTH MADE IN GERMANY does this by providing proactive support (including market and regulatory insight), introductory services, and

networking platforms including trade events at home and abroad. The initiative serves four major industries active in the international medical market: pharmaceuticals, medical technology, medical biotechnology, and digital health care.

HEALTH MADE IN GERMANY also works closely with 16 major German industry associations and is part of the BMWi's MITTELSTAND GLOBAL umbrella program for small and medium-sized enterprises. The initiative is ideally placed to provide access to German healthcare market information and to help overseas businesses identify potential German partners.

The HEALTH MADE IN GERMANY initiative is implemented by Germany Trade & Invest, the economic development agency of the Federal Republic of Germany, on behalf of the BMWi.



For more information: www.health-made-in-germany.com

Our support for your business:



We publish market briefs, in-depth market studies and company directories of the German healthcare industry and its different sectors.



Our calendar is regularly updated with the latest industry events in Germany and overseas.



We provide free access to 3.500+ German healthcare companies with our online database. Detailed company profiles and direct contact information help international businesses to identify potential suppliers and partners in Germany.



We take part in leading healthcare trade fairs all over the world, organize networking events and enjoy ongoing dialogue and exchange with international health policymakers.



Visit www.health-made-in-germany.com for more information about the German healthcare industry and all HEALTH MADE IN GERMANY activities.

Expert Advice



Axel Lohse is the manager responsible for the medical biotechnology and pharmaceutical industries at HEALTH MADE IN GERMANY. He is your point of contact for expert advice in those fields and looks forward to receiving your inquiries and requests.

Get in touch with us to learn more about what HEALTH MADE IN GERMANY can do for you.

Axel Lohse

Manager, Medical Biotechnology and Pharmaceuticals

T +49 30 200 099-254 Axel.Lohse@gtai.com www.health-made-in-germany.com www.gtai.com

Supported by:



on the basis of a decision by the German Bundestag

Imprint

Publisher

Germany Trade and Invest Gesellschaft für Außenwirtschaft und Standortmarketing mbH Friedrichstraße 60 10117 Berlin Germany

Executive Board

Dr. Jürgen Friedrich, Chairman/CEO Dr. Robert Hermann, CEO

Editor

Axel Lohse, Germany Trade & Invest, Berlin

Author

BIOCOM AG, Berlin

Layout

BIOCOM AG, Berlin

Print

Kern GmbH, 66450 Bexbach www.kerndruck.de

Notes

All rights reserved.

© Germany Trade & Invest, January 2020 Reproduction, in whole or in part, only permissible with express prior authorization. All market data provided is based on the most current market information available at the time of publication. Germany Trade & Invest accepts no liability for the actuality, accuracy, or completeness of the information provided.

Order Number

21169

Picture Credits

Title: Elnur/stock.adobe.com; page 2: Sergey/stock. adobe.com; page 4: Robert Przybysz/stock.adobe.com; page 6: nd3000/stock.adobe.com; page 7: Hoda Bogdan/stock.adobe.com; page 8: sergeyklopotov/stock.adobe.com; page 9: pressmaster/stock. adobe.com; page 10: Sved Oliver/stock.adobe.com; page 15: MyMicrostock/Stocksy/stock.adobe.com; page 72: Anna Om/stock.adobe.com; page 75: Illing & Vossbeck Fotografie

